Poster Presentations Session II

POSTER PRESENTATIONS SESSION II
SET-UP:	Tuesday May 19, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Tuesday May 19, 2009 - 8:00AM-7:30PM
POSTER AUTHOR DISCUSSION HOUR:	Tuesday May 19, 2009 - 6:00PM-7:00PM
DISMANTLE:	Tuesday May 19, 2009 - 7:30PM-8:00PM

HEALTH CARE USE & POLICY STUDIES Consumer Role in Health Care
PHP1	WITHDRAWN

PHP2	PHARMACY BENEFIT DESIGN AND PATIENT DRUG SUBSTITUTION
	Shang B
	The Urban Institute, Washington, DC, USA

PHP3	HEALTH CARE PATTERNS AND PATIENT SATISFACTION IN EUROPE: A COMPARISON OF SIX COUNTRIES
	Narayanan S¹, Potthoff P², Guether B²
	¹TNS Healthcare, New York, NY, USA, ²TNS Healthcare, Munich, Bavaria, Germany
HEALTH CARE USE & POLICY STUDIES Diagnosis Related Group
PHP4	CHANGES OF THE CASE-MIX INDEX OF THE HUNGARIAN INTENSIVE CARE UNITS
	Varga S¹, Bogár L¹, Sebestyén A², Vas G¹, Ágoston I¹, Kriszbacher I¹, Boncz I³
	¹University of Pécs, Pecs, Hungary, ²National Health Insurance Fund Administration, Budapest, Hungary, ³University of Pécs, Pécs, Hungary

PHP5	MARKET SHARE OF INTENSIVE CARE UNITS IN HUNGARY ACCORDING TO THE DRG SYSTEM
	Varga S¹, Bogár L¹, Sebestyén A², Nagy Z³, Ágoston I¹, Kriszbacher I¹, Boncz I⁴
	¹University of Pécs, Pecs, Hungary, ²National Health Insurance Fund Administration, Budapest, Hungary, ³Health Insurance Supervisory Authority, Budapest, Hungary, ⁴University of Pécs, Pécs, Hungary

HEALTH CARE USE & POLICY STUDIES Drug/Device/Diagnostic Use & Policy
PHP6	PHYSICIAN KNOWLEDGE OF THE FDA-APPROVED INDICATIONS OF COMMONLY PRESCRIBED DRUGS: RESULTS OF A NATIONAL SURVEY
	Moloney R¹, Chen D², Wynia MK³, Alexander GC¹
	¹University of Chicago, Chicago, IL, USA, ²University of Virginia, Charlottesville, VA, USA, ³American Medical Association, Chicago, IL, USA

PHP7	ABOLITION OF PRESCRIPTION CO-PAYMENTS: AN ANALYSIS OF ITEMS DISPENSED IN WALES
	Hughes DA¹, Alam FM², Cohen D², Dunstan F³, Groves S², Routledge PA³
	¹Bangor University, Bangor, UK, ²University of Glamorgan, Pontypridd, UK, ³Cardiff University, Cardiff, UK

PHP8	A COMPARISON OF POLICIES ON PAEDIATRIC DOSING GUIDELINES AND INDICATIONS BETWEEN THE UNITED STATES AND EUROPE
	Nixon F, Chan M, Lock K
	Heron Evidence Development Ltd, Luton, UK

PHP9	THE IMPACT OF LEGISLATION AND PRICING ON GENERIC DRUG UTILIZATION: AN ANALYSIS OF 26 COUNTRIES
	Patorno E, Margulis A, Cai S, Gagne JJ, Geisler BP, Li Q, Lin SW, Liu W, Palmsten K, Yau WP, Polinski JM
	Harvard School of Public Health, Boston, MA, USA

PHP10	CHARACTERISTICS OF MEDICARE PART-D ENROLLEES WITH AND WITHOUT PRESCRIPTION DRUG COVERAGE GAP
	Said Q, Li C, Hastings J, Souder E
	University of Arkansas for Medical Sciences, Little Rock, AR, USA

PHP11	THE IMPACT OF NON-REFERRAL OUTPATIENT CO-PAYMENT ON MEDICAL CARE UTILISATION AND EXPENDITURE IN TAIWAN
	Chen LC¹, Schafheutle E², Noyce P², Wen YH¹, Wu JS³
	¹Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ²University of Manchester, Manchester, UK, ³Bureau of National Health Insurance, Kaohsiung, Taiwan

PHP12	HOW NON-REFERRAL OUTPATIENT CO-PAYMENT IN TAIWAN IMPACTS ON PATIENTS' OUT-OF-POCKET COSTS AND PRESCRIPTION PATTERNS
	Chen LC¹, Schafheutle E², Noyce P², Wen YH¹, Wu JS³
	¹Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ²University of Manchester, Manchester, UK, ³Bureau of National Health Insurance, Kaohsiung, Taiwan

PHP13	COST-RELATED UNDERUSE OF MEDICINE DUE TO MEDICAID PHARMACY COST-CONTAINMENT POLICY ACTIONS
	Kaisaeng N, Zhang JX
	Virginia Commonwealth University, Richmond, VA, USA

PHP14	HAVE YOUR CAKE OR EAT IT: DO DECISIONS BASED ON COST-EFFECTIVENESS UNDERMINE INCENTIVES FOR RESEARCH AND DEVELOPMENT?
	Walker SM¹, Claxton K²
	¹University of York, York, North Yorkshire, UK, ²University of York, York, UK

PHP15	ASSESSMENT OF ORPHAN DRUGS DEVELOPED AND DRUG UTILIZATION UNDER THE ORPHAN DRUG ACT: A DESCRIPTIVE EMPIRICAL STUDY
	McErlane E¹, Desai P¹, Guo JJ¹, Sietsema W², Kelton CM¹
	¹University of Cincinnati, Cincinnati, OH, USA, ²Kendle International, Cincinnati, OH, USA

PHP16	MARKET DISCONTINUATION OF PHARMACEUTICALS IN THE UNITED STATES: ANALYSIS OF DRUGS APPROVED BY THE FDA FROM 1939 TO 2008
	Qureshi ZP¹, Szeinbach SL¹, Seoane-Vazquez E¹, Rodriguez-Monguio R²
	¹Ohio State University, Columbus, OH, USA, ²University of Massachusetts, Amherst, Amherst, MA, USA

PHP17	CONTENT ANALYSIS OF OFF-LABEL DRUG USE: REPORTING PRINT MEDIA COVERAGE
	Patel DA
	Virginia Commonwealth University, Richmond, VA, USA

PHP18	WASTED MEDICATION: HOW BIG IS THE PROBLEM?
	Ryvkin M, Garavaglia S
	Medco Health Solutions, Inc., Franklin Lakes, NJ, USA

PHP19	MEDICATION COSTS AND UTILIZATION IN A HOSPICE CARE
	Parekh RH, Kamal KM, Mihalyo M, Runyon A
	Duquesne University, Pittsburgh, PA, USA

PHP20	A PROGRAM EVALUATION OF A POLYPHARMACY SUB-POPULATION: MEDICATIONS, EMERGENCY ROOM VISITS, AND HOSPITALIZATIONS
	Bresnahan B¹, Koprowicz K¹, Roy Choudhury S², Wong E²
	¹University of Washington, Seattle, WA, USA, ²Premera Blue Cross, Mountlake Terrace, WA, USA

PHP21	USING EXPLICIT CRITERIA TO EVALUATE INAPPROPRIATE PRESCRIBING IN ELDERLY OUTPATIENTS: A COHORT STUDY
	Abouzaid S¹, Del Canale S², Maio V¹
	¹Thomas Jefferson University, Philadelphia, PA, USA, ²LHU Parma, Montechiarugolo, Parma, Italy

PHP22	POLYPHARMACY IS A MAJOR ISSUE IN THE ELDERLY POPULATION: EVIDENCE FROM A POPULATION-BASED STUDY IN PARMA, ITALY
	Abouzaid S¹, Del Canale S², Negri G³, Donatini A⁴, Maio V¹
	¹Thomas Jefferson University, Philadelphia, PA, USA, ²LHU Parma, Montechiarugolo, Parma, Italy, ³LHU Parma, Parma, Parma, Italy, ⁴LHU Parma, Parma, Italy

PHP23	DRUG USE AND EXPENDITURES FOR PART D ENROLLED SENIORS WHO REACHED THE COVERAGE GAP IN 2007
	Gadkari AS, Mott DA, Thorpe J
	University of Wisconsin-Madison, Madison, WI, USA

PHP24	COST SAVINGS ASSOCIATED WITH FILLING A THREE-MONTH SUPPLY OF PRESCRIPTION MEDICINES
	Rabbani A, Alexander GC
	University of Chicago, Chicago, IL, USA

PHP25	USING MEDICARE PART D DATA FOR RESEARCH
	Schneider KM, O'Donnell BE, Dean D
	Buccaneer Computer Systems & Service, Inc, West Des Moines, IA, USA

PHP26	THE IMPACT OF MEDICARE PART D ON MEDICARE-MEDICAID DUAL-ELIGIBLE BENEFICIARIES' PRESCRIPTION UTILIZATION AND EXPENDITURES
	Basu A, Yin W, Alexander GC
	University of Chicago, Chicago, IL, USA

PHP27	OPTIMIZING THE USE OF MEDICATION IN THE INTRAVENOUS COMPOUND CENTER OF THE CMNO
	Lomelí García M¹, Zapata L²
	¹CMNO, Guadalajara, Jalisco, Mexico, ²Guia Mark, Mexico, DF, Mexico

PHP28	TRENDS IN BEERS DRUG USE IN THE DUALLY ELIGIBLE MEDICARE AND MEDICAID POPULATION USING THE 1997 BEERS DRUG LIST FROM 1999 THROUGH 2004
	Montgomery MA, Ciborowski G, Blackwell SA, Baugh DK
	Centers for Medicare & Medicaid Services, Baltimore, MD, USA

PHP29	WITHDRAWN

PHP30	A SYSTEMATIC LITERATURE REVIEW OF ELECTRONIC MONITORING DEVICES FOR MEASURING MEDICATION ADHERENCE
	Shi L¹, Koleva YN¹, Chhabra P¹, Walker PD¹, Kalsekar A², Pawaskar MD³
	¹Tulane University, New Orleans, LA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Eli Lilly and Company, Indianpolis, IN, USA

PHP31	VARIABILITY OF FEES IN THE FIELD OF ULTRASOUND IN THE AUSTRIAN CONTRACTED PHYSICIANS' AND INSTITUTES' SECTOR
	Weisser A, Wilbacher I, Scholler C, Endel G
	Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria

HEALTH CARE USE & POLICY STUDIES Equity and Access
PHP32	EQUITY AND ACCESS TO GENERIC DRUGS: A COMPARISON OF GENERIC DRUG DISCOUNT PROGRAMS OFFERED BY CHAIN PHARMACIES IN THE UNITED STATES
	Dwibedi N¹, Patel H¹, Sansgiry SS²
	¹University of Houston, HOUSTON, TX, USA, ²University of Houston, Houston, TX, USA

PHP33	UNMET PRESCRIPTION MEDICATION NEED DUE TO COST, HEALTH PLAN PROBLEM, AND LACK OF INSURANCE OF CHILDREN IN THE UNITED STATES: RESULTS FROM NATIONAL SURVEY OF CHILDREN'S HEALTH 2003 DATA
	Mehta S, Nagar SP, Aparasu R
	University of Houston, Houston, TX, USA

PHP34	A NEW INEQUITY-IN-HEALTH INDEX BASED ON MILLENIUM DEVELOPMENT GOALS: METHODOLOGY AND VALIDATION
	Eslava-Schmalbach JH¹, Alfonso H², Oliveros H³, Gaitan-Duarte H¹, Agudelo C¹
	¹National University of Colombia, Bogota, D.C, Colombia, ²Unversity of Western Australia, Perth, WA, Australia, ³Universidad Militar Nueva Granada - Clínica San Rafael, Bogota, D.C, Colombia

PHP35	THE EFFECT OF THE WITHDRAWAL OF HOSPITAL DAILY FEE ON THE NUMBER OF ADMISSIONS TO ACUTE CARE HOSPITAL WARDS IN HUNGARY
	Boncz I¹, Kövi R², Kőrösi L², Vas G³, Varga S³, Kriszbacher I³, Betlehem J³, Gulácsi L⁴, Molnár A⁵, Sebestyén A⁵
	¹University of Pécs, Pécs, Hungary, ²National Health Insurance Fund Administration (OEP), Budapest, Hungary, ³University of Pécs, Pecs, Hungary, ⁴Corvinus University of Budapest, Budapest, Hungary, ⁵National Health Insurance Fund Administration, Budapest, Hungary

PHP36	EFFECT OF THE INTRODUCTION OF VISIT FEE ON THE NUMBER OF VISITS TO GENERAL PRACTITIONERS IN HUNGARY
	Kőrösi L¹, Kövi R¹, Varga S², Sebestyén A³, Kriszbacher I², Betlehem J², Brodszky V⁴, Karpati K⁴, Molnár A³, Boncz I⁵
	¹National Health Insurance Fund Administration (OEP), Budapest, Hungary, ²University of Pécs, Pecs, Hungary, ³National Health Insurance Fund Administration, Budapest, Hungary, ⁴Corvinus University of Budapest, Budapest, Hungary, ⁵University of Pécs, Pécs, Hungary

PHP37	REGIONAL VARIATION IN MEDICAID ENROLLMENT AMONG MEDICAL EXPENDITURE PANEL SURVEY (MEPS) POPULATION
	Zhao Y
	Tulane University, New Orleans, LA, USA

PHP38	THE POWER OF EPIDEMIOLOGICAL ESTIMATORS TO RATE INEQUALITIES IN HEALTH IN HIGH-INCOME OECD COUNTRIES, 1998-2002
	Eslava-Schmalbach JH¹, Alfonso H², Gaitan-Duarte H¹, Agudelo C¹
	¹National University of Colombia, Bogota, D.C, Colombia, ²Unversity of Western Australia, Perth, WA, Australia

PHP39	THE EFFECT OF THE WITHDRAWAL OF VISIT FEE ON THE NUMBER OF PATIENT-VISITS TO OUTPATIENT CARE DEPARTMENTS IN HUNGARY
	Kövi R¹, Kőrösi L¹, Sebestyén A², Ágoston I³, Nagy Z⁴, Kriszbacher I³, Oláh A³, Molnár A², Péntek M⁵, Boncz I⁶
	¹National Health Insurance Fund Administration (OEP), Budapest, Hungary, ²National Health Insurance Fund Administration, Budapest, Hungary, ³University of Pécs, Pecs, Hungary, ⁴Health Insurance Supervisory Authority, Budapest, Hungary, ⁵Flor Ferenc County Hospital, Kistarcsa, Hungary, ⁶University of Pécs, Pécs, Hungary

PHP40	EVALUATING COST/EQUITY IN THE COLOMBIAN HEALTH SYSTEM, 1998-2005
	Eslava-Schmalbach JH¹, Baron G², Gaitan-Duarte H¹, Alfonso H³, Agudelo C¹, Sanchez C⁴
	¹National University of Colombia, Bogota, D.C, Colombia, ²Inter-American Development Bank, Bogota, D.C, Colombia, ³Unversity of Western Australia, Perth, WA, Australia, ⁴Departamento Administrativo Nacional de Estadistica, Bogota, D.C, Colombia

PHP41	POCKET EXPENSES IN HEALTH IN COLOMBIA PER INCOME, 1997-2003
	Eslava-Schmalbach JH¹, Alfonso H², Gaitan-Duarte H¹, Agudelo C¹
	¹National University of Colombia, Bogota, D.C, Colombia, ²Unversity of Western Australia, Perth, WA, Australia

PHP42	REVIEW OF THE FINANCIAL MECHANISM OF SUDAN HEALTH SYSTEM
	Baloul IEEM¹, Maznah D², Awang ABM², Suleiman SA¹
	¹National Health Insurance Fund (NHIF), Khartoum, Sudan, ²Department of Social and Preventive Medicine (SPM)/ Faculty of Medicine/University of Malaya, Kuala Lumpur, Malaysia

HEALTH CARE USE & POLICY STUDIES Formulary Development
PHP43	DEVELOPING A FRAMEWORK FOR THE INCLUSION OF PHARMACEUTICALS IN HEALTH INSURANCE BENEFIT PACKAGE, A COMPARATIVE STUDY ON IRANIAN SOCIAL SECURITY ORGANIZATION
	Beyhaghi H¹, Basmenji K²
	¹Shahid Beheshti Medical University, Tehran, Tehran, Iran, ²Pioneers in Health Economics Institute, Tehran, Tehran, Iran

PHP44	WITHDRAWN

HEALTH CARE USE & POLICY STUDIES Health Care Costs & Management
PHP45	VARIABILITY OF FEES IN THE FIELD OF PHYSICAL THERAPY IN THE AUSTRIAN CONTRACT PHYSICIANS' AND INSTITUTES' SECTOR
	Wilbacher I, Scholler C, Weisser A, Endel G
	Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria

PHP46	EVALUATING COST DIFFERENCES AMONG OPERATIONAL TEAMS SUPPORTING THE INDIANA HEALTH INFORMATION EXCHANGE
	Bansal M¹, Grannis S², Kansky J³, Morrison W¹
	¹Indiana University, Indianapolis, IN, USA, ²The Regenstrief Institute, Inc, Indianapolis, IN, USA, ³Indiana Health Information Exchange, Indianapolis, IN, USA

PHP47	WITHDRAWN

PHP48	LEGISLATIVE ASPECTS OF HEALTH TECHNOLOGY ASSESSMENT IN SLOVAKIA
	Tomek D¹, Bielik J²
	¹Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, ²Trencin University, Trencin, Slovak Republic

PHP49	THE CHANGING DYNAMICS IN HEALTH CARE FUNDING
	Sparrowhawk K, Long M, Watch J
	PriceSpective, London, UK

PHP50	INCREMENTAL SICK LEAVE COSTS AND LOST TIME AMONG EMPLOYEES WITH PSYCHIATRIC AND MEDICAL CONDITIONS
	Brook RA¹, Kleinman NL², Melkonian AK³, Smeeding J⁴
	¹The JeSTARx Group, Newfoundland, NJ, USA, ²HCMS Group, Paso Robles, CA, USA, ³The HCMS Group, Cheyenne, WY, USA, ⁴The JeSTARx Group, Dallas, TX, USA

PHP51	DOES IMPROVING QUALITY OF CARE SAVE MONEY? ANALYSIS OF HEALTH CARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS) MEASURES
	Broder MS¹, Ory C¹, Yermilov I², Ko C², Maggard MA², Keeler EB³
	¹Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, ²UCLA Center for Surgical Outcomes and Quality, Los Angeles, CA, USA, ³RAND Health, Santa Monica, CA, USA

PHP52	BUDGETARY POLICIES AND AVAILABLE ACTIONS: A GENERALISATION OF DECISION RULES FOR ALLOCATION AND RESEARCH DECISIONS
	McKenna C¹, Chalabi Z², Epstein D¹, Claxton K¹
	¹University of York, York, UK, ²London School of Hygiene and Tropical Medicine, London, UK

PHP53	WITHDRAWN

PHP54	EVALUATING DIFFERENCES IN DRUG REIMBURSEMENT BETWEEN MAIL-ORDER AND COMMUNITY PHARMACY
	Visaria J¹, Seoane-Vazquez E¹, Rodriguez-Monguio R², Schwartzbaum J¹, Szeinbach SL¹
	¹Ohio State University, Columbus, OH, USA, ²University of Massachusetts, Amherst, Amherst, MA, USA

PHP55	TRENDS IN DESIGN CHARACTERISTICS OF BRIEF SUMMARY ON PRINT ADS OF PRESCRIPTION DRUGS: A FIVE YEAR STUDY
	Dwibedi N¹, Sansgiry SS²
	¹University of Houston, HOUSTON, TX, USA, ²University of Houston, Houston, TX, USA

PHP56	COMPRISON OF NOTIFIABLE DISEASES SURVELLIANCE WEBSITES OF FOUR COUNTRIES
	Agarwal SJ, Sansgiry SS
	University of Houston, Houston, TX, USA

PHP57	WITHDRAWN

PHP58	FACTORS ASSOCIATED WITH REPEAT ATTENDANCE AT EMERGENCY DEPARTMENT (ED) OF A SECONDARY CARE HOSPITAL IN SINGAPORE
	Paul P¹, Heng BH¹, Tay SY², Seow E³
	¹National Healthcare Group, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³Tan Tock Seng Hospital, Singapore, Singapore, Singapore

PHP59	INCIDENCE AND OUTCOMES OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG MEDICARE PART D PATIENTS
	Mendonca C, Lobb WB, Banahan BF, Wilkin NE, Pace PF
	University of Mississippi, University, MS, USA

PHP60	OVERVIEW OF POST-MARKETING DRUG SAFETY SURVEILLANCE IN SOME DEVELOPING COUNTRIES AND WELL DEVELOPED REGIONS
	Vaidya S¹, Guo JJ¹, Heaton PC¹, Steinbuch M²
	¹University of Cincinnati, Cincinnati, OH, USA, ²P&G Pharmaceuticals, Inc, Mason, OH, USA

PHP61	WITHDRAWN

PHP62	THE PRELIMINARY IMPACT OF HOSPITAL GLOBAL BUDGETING ON THE QUALITY OF CARE
	Lo JC
	Academia Sinica, Taipei, Taiwan

PHP63	USE OF READY-TO-USE (RTU) VERSUS CUSTOMIZED NUTRITION (CNF) FORMULATIONS AS A TOTAL PARENTERAL NUTRITION (TPN) ALTERNATIVE IN MEXICAN PUBLIC HEALTH CARE SYSTEM. A PHARMACOECONOMIC APPROACH
	Soria-Cedillo IF¹, Baca-Muro VI², Garcia-Contreras F³
	¹Research Consulting, Hacienda Ojo de Agua, State of Mexico, Mexico, ²Research Consulting, Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Mexico City, Mexico

PHP64	LINKING PAYMENT AND HEALTH OUTCOMES: A SYSTEMATIC REVIEW AND TAXONOMY OF PERFORMANCE-BASED HEALTH OUTCOMES AGREEMENTS BETWEEN HEALTH CARE PAYERS AND MANUFACTURERS
	Carlson JJ¹, Sullivan SD¹, Garrison LP¹, Neumann PJ², Veenstra DL¹
	¹University of Washington, Seattle, WA, USA, ²Tufts-New England Medical Center, Boston, MA, USA

PHP65	THE IMPACT AND CHALLENGES OF INCLUDING PATIENT COST SHARING IN COST-EFFECTIVENESS ANALYSES FROM THE PAYER PERSPECTIVE
	Spackman DE, Campbell JD
	University of Washington, Seattle, WA, USA

PHP66	EVALUATION OF THE FIRST-YEAR OPERATION OF KOREAN POSITIVE LIST SYSTEM FOR PHARMACEUTICAL REIMBURSEMENT
	Park SE, Yim EY, Lee SM, Choi HW, Kim JM, Lim SH, Kim KH, Yi SY
	Health Insurance Review & Assessment Service, Seoul, Seoul, South Korea

PHP67	HEALTH STATUS AND ATTITUDES TOWARDS HEALTH INSURANCE IN MEPS SAMPLE POPULATION
	Nadpara PA
	West Virginia University, Morgantown, WV, USA

HEALTH CARE USE & POLICY STUDIES Health Care Research & Education
PHP68	DISCHARGE AGAINST MEDICAL ADVICE (DAMA): THE CASE OF PAYER STATUS
	Mendonca CM, Banahan BF
	University of Mississippi School of Pharmacy, University, MS, USA

PHP69	PHARMACIST OPINION AND PERCEIVED CONFIDENCE IN KNOWLEDGE REGARDING THE IMPACT OF MEDICARE PART D PRESCRIPTION DRUG BENEFIT PROGRAM ON PATIENT CARE
	Goyal R, Makhija D, Sansgiry SS
	University of Houston, Houston, TX, USA

PHP70	ASSESSING THE EFFECT OF COST-SHARING ON EMERGENCY DEPARTMENT USE BY ECONOMICALLY DISADVANTAGED PERSONS
	Strassels SA¹, Rascati KL², Wilson JP²
	¹University of Texas at Austin College of Pharmacy, Austin, TX, USA, ²University of Texas at Austin, Austin, TX, USA

PHP71	HOW DO MANAGED PHYSICIAN PANELS COMPARE AGAINST NON-PANEL PHYSICIANS FOR THE PURPOSE OF RESEARCH?
	Narayanan S
	TNS Healthcare, New York, NY, USA

PHP72	PATIENT PRIVACY AND DATA CONFIDENTIALITY AND THE USE OF SECONDARY DATA
	Dean BB¹, Aguilar D¹, Whyte J², Nordyke R²
	¹Cerner LifeSciences, Beverly Hills, CA, USA, ²Amgen, Inc., Thousand Oaks, CA, USA

PHP73	HEALTH TECHNOLOGY ASSESSMENT IN DEVELOPING COUNTRIES: WHAT IS THE STATE OF PLAY?
	Shankland B, Mendes da Costa S
	Double Helix Consulting, London, UK

PHP74	WITHDRAWN

PHP75	PHYSICIAN KNOWLEDGE AND CONFIDENCE IN APPROPRIATE MEDICATION PRESCRIBING IN THE ELDERLY: A SURVEY STUDY IN PARMA, ITALY
	Maio V¹, Abouzaid S¹, Negri G², Donatini A³
	¹Thomas Jefferson University, Philadelphia, PA, USA, ²LHU Parma, Parma, Parma, Italy, ³LHU Parma, Parma, Italy

PHP76	25 YEARS OF ECONOMIC EVALUATION IN MEXICO: A SYSTEMATIC REVIEW OF ARTICLES PUBLISHED IN THE ECONOMIC AND MEDICAL LITERATURE: 1984-2009
	Mould-Quevedo J¹, Contreras-Hernandez I²
	¹Pfizer Mexico, Mexico City, Mexico, ²Social Security Mexican Institute, Mexico City, Mexico

PHP77	MEXICAN POSTER PRESENTATIONS AT ISPOR MEETINGS: A QUALITY AND TENDENCY ASSESSMENT 2003-2008
	Mould-Quevedo J¹, Contreras-Hernandez I²
	¹Pfizer Mexico, Mexico City, Mexico, ²Social Security Mexican Institute, Mexico City, Mexico

PHP78	THE STATUS QUO OF THE USAGE OF CHINESE VERSIONS OF GENERIC HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS
	Li MH¹, Liu G², Luo N³
	¹China Pharmaceutical University, Nanjing, Jiangsu, China, ²Peking University, Beijing, Beijing, China, ³National University of Singapore, Singapore, Singapore

PHP79	ASSESSING THE QUALITY OF CARE IN ITALY'S PRIMARY CARE PRACTICES USING ADMINISTRATIVE DATA. IS IT FEASIBLE?
	Maio V¹, Bassi MB², Abouzaid S¹, Pinotti M², Riccò D²
	¹Thomas Jefferson University, Philadelphia, PA, USA, ²LHU Reggio Emilia, Reggio Emilia, Italy

PHP80	AN EVALUATION OF PHARMACOECONOMICS EDUCATION IN COLLEGES OF PHARMACY OUTSIDE THE UNITED STATES 2007-2008 UPDATE
	Reddy M, Rascati KL, Wilson JP, Nwokeji ED
	University of Texas, Austin, TX, USA

HEALTH CARE USE & POLICY STUDIES Health Technology Assessment Programs
PHP81	ADDRESSING THE CHALLENGE OF IMPLEMENTING HEALTH TECHNOLOGIES: THE SPANISH EXPERIENCE
	Paz S¹, Lizan L¹, Rodriguez JM², Anton E²
	¹Jaume I University, Castellon, Spain, ²Medtronic Iberia, Madrid, Spain

PHP82	USE OF INDIRECT COMPARISON IN HTA SUBMISSIONS
	Buckley F¹, Modha R¹, Muston D², Misra A³, Williams R³
	¹Heron Evidence Development Ltd, Luton, UK, ²Heron Evidence Development Ltd, Stopsley, Luton, UK, ³Amgen, Inc., Thousand Oaks, CA, USA

PHP83	WHAT IS THE FUTURE IN THE IMPLEMENTATION OF HEALTH TECHNOLOGIES IN THE PUBLIC SECTOR IN SPAIN? A QUALITATIVE STUDY EXPLORING KEY DECISION-MAKERS' PERSPECTIVES
	Paz S¹, Lizan L¹, Rodriguez JM², González P²
	¹Jaume I University, Castellon, Spain, ²Medtronic Iberia, Madrid, Spain

PHP84	A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION ACROSS FOUR HEALTH TECHNOLOGY APPRAISAL SYSTEMS CATEGORISED BY DISEASE
	Plested M, Karia R, Samuels ER
	Heron Evidence Development Ltd, Luton, UK

PHP85	REVIEW OF HTA RECOMMENDATIONS FOR DRUG THERAPIES IN POLAND ISSUED FROM SEPTEMBER 6, 2007 UNTIL OCTOBER 28, 2008 BY THE CONSULTATIVE COUNCIL (APPRAISAL COMMITTEE) OF AHTAPOL IN POLAND
	Kolasa K
	AstraZeneca, sÖDERTÄLJE, Sweden

PHP86	PUBLICATION TRENDS OF BUDGET IMPACT ANALYSES OVER THE PAST SIX YEARS
	Pathak P, Kowal-Podmore S, Munakata J
	IMS Health, Falls Church, VA, USA

PHP87	THE IMPACT OF THE SUBMISSION SEQUENCE – WHICH APPRAISING BODY TO SUBMIT TO FIRST?
	Karia R, Plested M
	Heron Evidence Development Ltd, Luton, UK

PHP88	IDENTIFYING KEY DECISION PATHWAYS IN HEALTH TECHNOLOGY ASSESSMENT AROUND THE WORLD
	Sullivan N¹, Szeinbach SL², Seoane-Vazquez E², Chhabra A³, Faulkner EC⁴, Holtorf AP⁵, Polygenis D⁶, Rebeira M⁷, Rodriguez JM⁸, Matuszewski K⁹
	¹Technology Assessment Evaluation Group LLC, Encinitas, CA, USA, ²Ohio State University, Columbus, OH, USA, ³Pfizer, New York, NY, USA, ⁴RTI Health Solutions, Research Triangle Park, NC, USA, ⁵University of Utah, Salt Lake City, UT, USA, ⁶McKesson Phase 4 Solutions, Toronto, ON, Canada, ⁷Bayer HealthCare, Toronto, ON, Canada, ⁸Medtronic Iberia, Madrid, Spain, ⁹University HealthSystem Consortium, Oak Brook, IL, USA

PHP89	APPLES AND ORANGES? COMPARATIVE EFFECTIVENESS IN THE UNITED STATES AND OTHER COUNTRIES
	Levy AR¹, Johnston KM², Mitton C³, Risebrough N¹, Harrigan B¹, Briggs A⁴
	¹Oxford Outcomes Ltd, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia Okanagan, Kelowna, BC, Canada, ⁴University of Glasgow, Glasgow, UK

HEALTH CARE USE & POLICY STUDIES Prescribing Behavior & Treatment Guidelines
PHP90	THE IMPACT OF AN ELECTRONIC PRESCRIBING SOLUTION ON THE SELECTION AND PRESCRIBING OF COST-EFFECTIVE THERAPEUTIC OPTIONS
	Hutchins DS¹, Liberman JN², Berger JE³, Jan SA⁴, Johnson MM⁴
	¹CVS Caremark Corporation, Scottsdale, AZ, USA, ²CVS Caremark Corporation, Hunt Valley, MD, USA, ³CVS Caremark Corporation, Northbrook, IL, USA, ⁴Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA

PHP91	MEDICARE PART D'S EFFECT ON PRESCRIBING VOLUME: AVERAGE MONTHLY UTILIZATION OF SELECTED HIGH USE DRUGS IN THE PROTECTED CLASSES BY DIFFERENT SPECIALTIES
	White C¹, Sepulveda B², Doyle JJ³
	¹Quintiles Consulting, Hawthorne, NY, USA, ²Global Market Access, Quintiles Consulting, Hawthorne, NY, USA, ³Quintiles Global Consulting, Hawthorne, NY, USA

PHP92	EVALUATION OF A WIRELESS HANDHELD MEDICATION MANAGEMENT PROGRAM IN THE PREVENTION OF DRUG-DRUG INTERACTIONS
	Saverno K, Malone DC
	University of Arizona College of Pharmacy, Tucson, AZ, USA

PHP93	PRESCRIPTION PATTERNS OF CHINESE HERBAL PRODUCTS SUSPECTED OF CONTAINING ARISTOLOCHIC ACID: ANALYSIS OF REIMBURSEMENT DATA OF A COHORT FROM TAIWAN DURING 1997-2003
	Hsieh SC¹, Wang JD²
	¹Center for Drug Evaluation, Taipei City, Taiwan, ²National Taiwan University, College of Public Health, Taipei, Taiwan

PHP94	WHEN COMPARATIVE EVIDENCE IS UNCERTAIN: USE OF QUANTITATIVE CONSENSUS METHODS TO FILL IN GAPS
	Miller RM, Dubois R
	Cerner LifeSciences, Beverly Hills, CA, USA

HEALTH CARE USE & POLICY STUDIES Quality of Care
PHP95	MEDICATION ADMINISTRATION PROCESS CONDUCTED BY NURSES IN INTENSIVE AND ACUTE CARE UNITS OF A HOSPITAL: A TIME AND MOTION STUDY
	Dasgupta A¹, Sansgiry S², Frost C³, Tipton J³, Sherer J²
	¹University of Texas at Austin, Austin, TX, USA, ²University of Houston, Houston, TX, USA, ³St. Luke's Episcopal Hospital, Houston, TX, USA

POSTER PRESENTATIONS SESSION II
SET-UP:	Tuesday May 19, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Tuesday May 19, 2009 - 8:00AM-7:30PM
POSTER AUTHOR DISCUSSION HOUR:	Tuesday May 19, 2009 - 6:00PM-7:00PM
DISMANTLE:	Tuesday May 19, 2009 - 7:30PM-8:00PM

DIABETES/ENDOCRINE DISORDERSClinical Outcomes Studies
PDB1	LITERATURE REVIEW OF THE IMPACT OF OBESITY ON CARDIOVASCULAR OUTCOMES IN THE GENERAL POPULATION AND IN PATIENTS WITH TYPE-2 DIABETES
	Smith-Palmer J¹, Kalsekar A², Boye KS², Goodall G¹
	¹IMS Health, Basel, Switzerland, ²Eli Lilly and Company, Indianapolis, IN, USA

PDB2	A1C AND WEIGHT OUTCOMES FOLLOWING 6 MONTHS OF ANALOG BASAL INSULIN IN INSULIN NAÏVE PATIENTS WITH TYPE-2 DIABETES IN AN AMBULATORY CARE SETTING
	McAdam-Marx C¹, Brixner D¹, Ye X¹, Misurski D², Fabunmi R³
	¹University of Utah College of Pharmacy, Salt Lake City, UT, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Amylin Pharmaceuticals, Inc., San Diego, CA, USA

PDB3	EFFECTS OF SUSTAINED-RELEASE VERSUS IMMEDIATE-RELEASE GLIPIZIDES FOR TYPE-2 DIABETES MELLITUS: A SYSTEMATIC REVIEW OF 16 RANDOMIZED TRIALS
	Wang L¹, Li Y²
	¹Sichuan University, Chengdu, Sichuan, China, ²West China Hospital, Sichuan University, Chengdu, China

PDB4	METFORMIN TREATMENT FOR IMPROVING OUTCOMES RELATED TO INFERTILITY IN POLYCYSTIC OVARY SYNDROME - A BAYESIAN ANALYSIS
	Perera PN, Malone DC
	University of Arizona College of Pharmacy, Tucson, AZ, USA

PDB5	SYSTEMATIC REVIEW IN TYPE-2 DIABETES – WHAT IS THE INFLUENCE OF LIFESTYLE CHANGE?
	Arora A¹, Aneja G¹, Shukla H¹, Alnwick K²
	¹Heron Health Private Limited, Chandigarh, India, ²Heron Evidence Development Ltd, Letchworth Garden City, UK

PDB6	18 MONTH A1C AND WEIGHT OUTCOMES OF EXENATIDE THERAPY IN PATIENTS WITH TYPE-2 DIABETES IN A REAL-WORLD STUDY
	Brixner D¹, McAdam-Marx C¹, Ye X¹, Misurski D², Wintle M³, Fabunmi R³
	¹University of Utah College of Pharmacy, Salt Lake City, UT, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Amylin Pharmaceuticals, Inc., San Diego, CA, USA

PDB7	ADMINISTRATIVE CLAIMS ANALYSIS OF PATIENTS WITH TYPE-2 DIABETES INITIATING SITAGLIPTIN THERAPY
	Fabunmi R¹, Wade R², Quimbo RA³, Hou L³, Pawaskar MD⁴, Misurski D⁴
	¹Amylin Pharmaceuticals, Inc., San Diego, CA, USA, ²HealthCore, Inc., Wilmington, DC, USA, ³HealthCore, Inc., Wilmington, DE, USA, ⁴Eli Lilly and Company, Indianapolis, IN, USA

PDB8	COMPARISON OF DOSING PATTERNS OF DULOXETINE AND PREGABALIN AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN
	Sun P¹, Zhao Y², Bledsoe S², Watson PR²
	¹Kailo Research Group, Indianapolis, IN, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PDB9	THE EFFECTS OF SUSTAINED-RELEASE GLIPIZIDE VERSUS GLICLAZIDE FOR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
	Wang L¹, Li Y²
	¹Sichuan University, Chengdu, Sichuan, China, ²West China Hospital, Sichuan University, Chengdu, China

PDB10	A COMPARISON OF ECONOMIC OUTCOMES BETWEEN ADHERENT AND NONADHERENT PATIENTS TREATED WITH ORAL ANTIDIABETIC MEDICATIONS
	Hansen RA¹, Farley JF¹, Droege M², Maciejewski ML³
	¹University of North Carolina, Chapel Hill, NC, USA, ²Takeda Pharmaceuticals North America, Inc, Deerfield, IL, USA, ³Center for Health Services Research in Primary Care, Durham, NC, USA

PDB11	EFFECT OF ACE INHIBITORS AND ARBS ON INCIDENCE OF RENAL DISEASE IN ELDERLY PATIENTS WITH DIABETES
	Yadav R¹, Agarwal SJ¹, Desai R¹, Chitnis A¹, Morgan R², Johnson M¹, Chen H¹
	¹University of Houston, Houston, TX, USA, ²University of Texas, Houston, TX, USA

PDB12	RISK FACTORS FOR DEMENTIA IN ELDERLY PATIENTS WITH DIABETES MELLITUS
	Parikh NM¹, Morgan R², Kunik M³, Schulz P⁴, Chen H⁵, Aparasu R⁵, Yadav R⁵, Johnson M⁵
	¹Analysis Group, Inc., Boston, MA, USA, ²University of Texas, Houston, TX, USA, ³Center of Quality of Care and Utilization Studies, Veterans Affairs Medical Center, Houston, TX, USA, ⁴Baylor Neurology, Houston, TX, USA, ⁵University of Houston, Houston, TX, USA

PDB13	PATTERNS AND POTENTIAL RISKS OF CO-PRESCRIBING ANTIHYPERGLYCEMICS AND SILYMARIN: A TAIWANESE POPULATION-BASED STUDY
	Chan AL¹, Leung HW², Chien TW³
	¹Chi-Mei Medical Center, Taianan, Taiwan, ²Chi-Mei Medical Center, Tainan, Taiwan, ³Chi-Mei Medical Center, Yung Kang, Tainan, Taiwan

PDB14	FORECASTING THE NUMBER OF DIABETIC PATIENTS IN THE UNITED STATES THROUGH 2025
	Baser O¹, Wang L²
	¹University of Michigan and STATinMED Research, Ann Arbor, MI, USA, ²STATinMED Research, Ann Arbor, MI, USA

PDB15	UTILIZATION PATTERNS AND HYPOGLYCEMIA IN PATIENTS WITH TYPE-2 DIABETES ON CONCOMITANT EXENATIDE AND LONG-ACTING INSULIN THERAPY
	Wade R¹, Quimbo RA², Fabunmi R³, Blickensderfer AL³, Pawaskar MD⁴, Misurski D⁴
	¹HealthCore, Inc., Wilmington, DC, USA, ²HealthCore, Inc., Wilmington, DE, USA, ³Amylin Pharmaceuticals, Inc., San Diego, CA, USA, ⁴Eli Lilly and Company, Indianapolis, IN, USA

PDB16	REPLICATION AND VALIDATION OF THE QUANTIFICATION OF THE RELATIONSHIP BETWEEN PHARMACOLOGIC INTERVENTION, REDUCTIONS IN HBA1C AND REDUCTIONS IN COMPLICATIONS: ITS APPLICATION IN QUANTIFYING THE BENEFITS OF ADDING COLESEVELAM HYDROCHLORIDE TO METFORMIN IN TYPE-2 DIABETICS
	Simons WR¹, Hagan MA²
	¹Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, ²Daiichi Sankyo, Inc., Wayne, NJ, USA

PDB17	GLYCEMIC VARIABILITY AND COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS: EVIDENCE FROM A SYSTEMATIC REVIEW OF THE LITERATURE
	Nalysnyk L¹, Hernandez M¹, Xavier N², Krishnarajah G³
	¹United BioSource Corporation, Lexington, MA, USA, ²United BioSource Corporation, lexington, MA, USA, ³Bristol-Myers Squibb, Princeton, NJ, USA

DIABETES/ENDOCRINE DISORDERS Cost Studies
PDB18	A BUDGET IMPACT MODEL (BIM) TO ASSESS THE IMPACT ON THE ITALIAN NATIONAL HEALTH SERVICE (INHS) BUDGET OF THE INTRODUCTION OF MIMPARA (CINACALCET) IN THE NEW INDICATION PRIMARY HYPERPARATIROIDISM (PHPT)
	Dansi F¹, Chiroli S², Robbins S², Lu ZJ³
	¹AMGEN DOMPE, MILAN, Italy, ²Amgen Europe GMBH, Zug, Switzerland, ³Amgen, Inc., Thousand Oaks, CA, USA

PDB19	ECONOMIC EVALUATION OF LONG TERM SOMATOSTATIN ANALOGS IN THE TREATMENT OF ACROMEGALY IN MEXICO: MONOTHERAPY VS SEQUENTIAL THERAPY
	Salinas Escudero G¹, Idrovo J², Rivas R², Zapata L²
	¹Hospital Infantil de México Federico Gómez, México DF, Distrito Federal, Mexico, ²Guia Mark, Mexico, DF, Mexico

PDB20	COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO INSULIN DETEMIR FROM ORAL ANTIDIABETICS OR NPH IN THE CZECH SETTING; DATA FROM THE PREDICTIVE STUDY
	Doležal T¹, Písaríková Z¹, Rychna K², Honka M³, Bartášková D⁴
	¹Charles University in Prague, Prague 10, Czech Republic, ²Novo Nordisk s.r.o, Praha 6, Czech Republic, ³Faculty Hospital Ostrava, Ostrava, Czech Republic, ⁴Charles University in Prague, Prague 5, Czech Republic

PDB21	ECONOMIC EVALUATION OF RAPID-ACTING INSULIN ANALOGUES FOR THE TREATMENT OF PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS IN CANADA
	Belanger D, Cameron CG
	Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada

PDB22	ECONOMIC EVALUATION OF LONG-ACTING INSULIN ANALOGUES FOR THE TREATMENT OF PATIENTS WITH TYPE-1 AND TYPE-2 DIABETES MELLITUS IN CANADA
	Belanger D, Cameron CG
	Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada

PDB23	ECONOMIC EVALUATION OF METFORMIN, METFORMIN + SIBUTRAMIN OR ACARBOSE IN THE MANAGEMENT OF OVERWEIGHT AND OBESE DIABETES PATIENTS
	Salinas Escudero G¹, Idrovo J², Zapata L²
	¹Hospital Infantil de México Federico Gómez, México DF, Distrito Federal, Mexico, ²Guia Mark, Mexico, DF, Mexico

PDB24	COMPARISON OF GLUCOMETERS USED FOR SELF-MONITORING BLOOD GLUCOSE AMONG DIABETIC PATIENTS: A COST MINIMIZATION APPROACH.
	Goyal R, Sansgiry SS
	University of Houston, Houston, TX, USA

PDB25	USE OF GENERALIZED LINEAR MODEL TO FIND THE RELATIONSHIP BETWEEN DIAGNOSIS AND THE COST OF DIABETIC OUTPATIENTS
	Wang X
	University of Louisville, Louisville, KY, USA

PDB26	RACE AND GENDER DIFFERENCES IN ECONOMIC BURDEN OF DIABETES HOSPITALIZATIONS IN TENNESSEE
	White-Means S, Franklin BE, Brown LT
	University of Tennessee Health Science Center, Memphis, TN, USA

PDB27	DIRECT COST OF DIABETES IN OPD CLINICS OF PAKISTAN
	Khowaja LA, Khuwaja AK
	Aga Khan University, Karachi, Sindh, Pakistan

PDB28	EXCESS COSTS OF DIABETES MELLITUS AMONG MEDICARE RECIPIENTS IN A SKILLED NURSING FACILITY SETTING
	Boulanger L¹, Kongsø JH², Bouchard JR³, Christensen T⁴, Fraser K¹, Russell MW¹
	¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Novo Nordisk A/S, Bagsvaerd, Denmark, ³Novo Nordisk, Inc., Princeton, NJ, USA, ⁴Novo Nordisk A/S, Bagsværd, Denmark

PDB29	WITHDRAWN

PDB30	IMPROVEMENT IN CARDIOVASCULAR RISK FACTORS AND LONG-TERM OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES TREATED WITH LIRAGLUTIDE OR GLIMEPIRIDE MONOTHERAPY
	Alfonso R¹, Sullivan SD¹, Conner C², Hammer M³, Blonde L⁴
	¹University of Washington, Seattle, WA, USA, ²Novo Nordisk, Inc., Princeton, NJ, USA, ³Novo Nordisk A/S, Bagsværd, Denmark, ⁴Ochsner Medical Center, New Orleans, LA, USA

PDB31	LONG-TERM OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES RECEIVING GLIMEPIRIDE COMBINED WITH LIRAGLUTIDE OR ROSIGLITAZONE
	Alfonso R¹, Sullivan SD¹, Conner C², Hammer M³, Blonde L⁴
	¹University of Washington, Seattle, WA, USA, ²Novo Nordisk, Inc., Princeton, NJ, USA, ³Novo Nordisk A/S, Bagsværd, Denmark, ⁴Ochsner Medical Center, New Orleans, LA, USA

PDB32	CHANGES IN OPIOID USE AND ECONOMIC OUTCOMES AMONG DIABETIC PERIPHERAL NEUROPATHIC PAIN PATIENTS TREATED WITH DULOXETINE
	Boulanger L¹, Wu N¹, Chen SY¹, Fraser K¹, Zhao Y²
	¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PDB33	DAILY AVERAGE CONSUMPTION OF BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES
	McAdam-Marx C¹, Yu J¹, Shankar V², Bouchard JR³, Brixner D¹
	¹University of Utah College of Pharmacy, Salt Lake City, UT, USA, ²SDI, Plymouth Meeting, PA, USA, ³Novo Nordisk, Inc., Princeton, NJ, USA

DIABETES/ENDOCRINE DISORDERS Patient-Reported Outcomes Studies
PDB34	THE EFFECT OF MEDICATION CHOICE BETWEEN DULOXETINE AND PREGABALIN ON MEDICATION COMPLIANCE AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN
	Sun P¹, Zhao Y², Bledsoe S², Watson PR²
	¹Kailo Research Group, Indianapolis, IN, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PDB35	MEDICATION NON-ADHERENCE AND NON-PERSISTENCE IN A MANAGED CARE DIABETES MELLITUS POPULATION
	Nichol MB¹, Wu J¹, Knight TK¹, Liberman JN²
	¹University of Southern California, Los Angeles, CA, USA, ²CVS Caremark Corporation, Hunt Valley, MD, USA

PDB36	IMPACT OF TREATMENT COMPLEXITY ON ADHERENCE AND GLYCEMIC CONTROL: AN ANALYSIS OF ORAL ANTI-DIABETIC AGENTS
	Pollack M¹, Chastek B², Williams S³
	¹AstraZeneca, LP, Wilmington, DE, USA, ²i3 Magnifi, An Ingenix Company, Eden Prairie, MN, USA, ³AstraZeneca, Wilmington, DE, USA

PDB37	HYBRID APPLICATIONS OF EXACT COVARIATE MATCHING AND PROPENSITY SCORE IN THE EVALUATION OF PATIENT PERSISTENCE
	Yang G, Henderson SC
	IMS Health, Blue Bell, PA, USA

PDB38	THE EFFECT OF WEIGHT CHANGES ON HEALTH-RELATED QUALITY OF LIFE AND WORK IMPAIRMENT IN PATIENTS WITH TYPE 2 DIABETES
	Krishnarajah G¹, DiBonaventura M², Wagner S³, Gupta S⁴
	¹Bristol-Myers Squibb, Princeton, NJ, USA, ²Consumer Health Sciences, new York, NY, USA, ³Consumer Health Sciences International, Princeton, NJ, USA, ⁴Consumer Health Sciences, Princeton, NJ, USA

PDB39	DEVELOPMENT OF A VALUATION FUNCTION FOR A DIABETES-SPECIFIC PREFERENCE-BASED MEASURE OF HEALTH BASED ON THE MULTI-ATTRIBUTE UTILITY THEORY
	Sundaram M¹, Smith MJ², Revicki D³, Miller LA⁴, Madhavan SS²
	¹QualityMetric Incorporated, Lincoln, RI, USA, ²West Virginia University, Morgantown, WV, USA, ³United BioSource Corporation, Bethesda, MD, USA, ⁴University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

PDB40	THE IMPACT OF FREQUENCY AND SEVERITY OF SELF-REPORTED HYPOGLYCEMIA ON QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH ORAL ANTI-HYPERGLYCEMIC AGENTS
	Marrett E, Zhang Q, Radican L
	Merck & Co., Inc., Whitehouse Station, NJ, USA

PDB41	THE HANDLING OF GLUCOSE MONITORING AND INSULIN TREATMENT (HAGLUMIT) QUESTIONNAIRE CAPTURES HANDLING DIFFERENCES BETWEEN DIFFERENT SITUATIONS AND SYSTEMS FOR MONITORING BLOOD GLUCOSE IN DIABETES
	Mast O¹, Schmidt U²
	¹Roche Diagnostics, Ltd, Mannheim, Germany, ²Roche Diagnostics, Ltd, Mannheim, Baden-Württember, Germany

PDB42	PERCEPTION VERSUS REALITY -- CATEGORISATION OF PATIENT WEIGHT BY TYPE 2 DIABETES (T2DM) PATIENTS AND THEIR PHYSICIANS IN THE US AND EUROPE
	Stahl E¹, Benford M², Leith A², Colclough HA³, Watmough A², Grandy S⁴
	¹AstraZeneca R&D Lund, Lund, Sweden, ²Adelphi Group Products, Bollington, Cheshire, UK, ³Adelphi Group Products, Chesire, UK, ⁴AstraZeneca, Wilmington, DE, USA

PDB43	PATIENT REPORTED OUTCOMES ARE SUPERIOR IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH LIRAGLUTIDE AS COMPARED TO EXENATIDE, WHEN ADDED TO METFORMIN, SULFONYLUREA OR BOTH
	Schmidt WE¹, Christiansen JS², Hammer M³, Zychma MJ⁴, Buse J⁵
	¹Ruhr University, Bochum, Germany, ²Århus University Hospital, Århus, Denmark, ³Novo Nordisk A/S, Bagsværd, Denmark, ⁴Novo Nordisk A/S, Bagsvaerd, Denmark, ⁵University of North Carolina School of Medicine, Chapel Hill, NC, USA

PDB44	EFFECTS OF INSULIN THERAPY ON THE DIABETES SYMPTOM CHECKLIST-REVISED (DSC-R): DATA FROM A LARGE INSULIN CLINICAL TRIAL
	Nelson L¹, McLeod LD¹, Lee LJ², Hill C¹, Sweeney C¹, Sun P³, Fahrbach J², Martin S², Weinstock RS⁴
	¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Kailo Research Group, Indianapolis, IN, USA, ⁴SUNY Upstate Medical University and the Department of Veterans Affairs Medical Center, Syracuse, NY, USA

PDB45	SATISFACTION WITH DIABETES TREATMENTS: IMPACTS ON PATIENT HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY
	Pollack M¹, Waterman F², Bolge SC³, Williams S⁴
	¹AstraZeneca, LP, Wilmington, DE, USA, ²Consumer Health Sciences, New York, NY, USA, ³Consumer Health Sciences International, Princeton, NJ, USA, ⁴AstraZeneca, Wilmington, DE, USA

PDB46	CONTRIBUTIONS OF AND RELATIONSHIP BETWEEN EXPECTATIONS ABOUT AND EXPERIENCES WITH INSULIN THERAPY TO TREATMENT SATISFACTION IN INSULIN-NAÏVE PATIENTS WITH TYPE-2 DIABETES
	Naegeli AN, Hayes RP
	Eli Lilly and Company, Indianapolis, IN, USA

PDB47	THE ASSOCIATION BETWEEN PATIENT-REPORTED DIABETES SYMPTOMS AND TOLERABILITY ISSUES OF ORAL ANTIDIABETIC AGENTS ON WORK AND LIFE PRODUCTIVITY
	Pollack M¹, Bolge SC², Williams S¹, Waterman F³
	¹AstraZeneca, Wilmington, DE, USA, ²Consumer Health Sciences International, Princeton, NJ, USA, ³Consumer Health Sciences, New York, NY, USA

DIABETES/ENDOCRINE DISORDERS Health Care Use & Policy Studies
PDB48	GEOGRAPHIC VARIATION IN MEDICATION ADHERENCE
	Gibson TB¹, Batata A², Chernew ME³
	¹Thomson Reuters Healthcare, Ann Arbor, MI, USA, ²Pfizer, New York, NY, USA, ³Harvard Medical School, Boston, MA, USA

PDB49	THE EFFECT OF READINESS TO CHANGE ON MEASURES OF DIABETES CONTROL AND ATTITUDES TOWARDS DIABETES
	Beaton SJ¹, Sperl-Hillen JM², Von Worley A¹, Baumer D¹, Fernandes OD², Davis HT¹
	¹Lovelace Clinic Foundation, Albuquerque, NM, USA, ²HealthPartners Research Foundation, Bloomington, MN, USA

PDB50	STATUS OF DIABETES CONTROL AMONG COMMUNITY PHARMACY USERS WITH DIABETES: AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY
	Wang J¹, Thomas J², Byrd D³, Nola K⁴, Liu J⁵
	¹University of Tennessee Health Science Center, Memphis, TN, USA, ²University of Tennessee, Memphis, TN, USA, ³University of Tennessee, Knoxville, TN, USA, ⁴Pfizer, Franklin, TN, USA, ⁵East Tennessee State University, Johnson City, TN, USA

PDB51	ASSOCIATION BETWEEN MEDICATION ADHERENCE AND HBA1C LEVELS IN DIABETIC PARTICIPANTS ENROLLED IN A DISEASE MANAGEMENT PROGRAM
	Iyer RG¹, Cooper JG², Soucy AB², Krueger AC²
	¹CVS Caremark Corporation, Northbrook, IL, USA, ²CVS Caremark Corporation, Greensboro, NC, USA

PDB52	THE UTILITY OF A PRIOR-AUTHORIZATION REQUIREMENT FOR IMPLEMENTING RECOMMENDATIONS FOR HBA1C TESTING IN A MANAGED CARES SETTING IN ISRAEL
	Kahan NR, Waitman DA, Blackman S, Vardy DA
	Leumit Health Fund, Tel-Aviv, Israel

PDB53	SHORT-TERM OUTCOMES FOR AN EMPLOYER SPONSERED PHARMACIST- PROVIDED MULTI CENTER DIABETES MANAGEMENT PROGRAM
	Pinto S, Kumar J
	University of Toledo, Toledo, OH, USA

PDB54	DULOXETINE THERAPY AND CHANGES IN OPIOID USE AMONG DIABETIC PERIPHERAL NEUROPATHIC PAIN PATIENTS
	Wu N¹, Zhao Y², Boulanger L¹, Fraser K¹, Chen SY¹
	¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PDB55	UTILIZATION OF ANTIDIABETIC MEDICATIONS OF PATIENTS WITH TYPE 2 DIABETES COVERED BY VARIOUS TYPES OF HEALTH INSURANCE IN A US NATIONAL REPRESENTATIVE POPULATION IN YEAR 2005-2006
	Deng L
	Quantitative HealthCare Lab, Clinton, NJ, USA

PDB56	THE EFFECT OF VALUE-BASED INSURANCE DESIGN ON ADHERENCE TO DIABETES MEDICATIONS: A MATCHED DIFFERENCE IN DIFFERENCE EVALUATION
	Zeng F¹, An JJ², Patel BV¹, Scully R³, Barrington C³
	¹MedImpact Healthcare Systems, Inc., San Diego, CA, USA, ²University of Southern California, Los Angeles, CA, USA, ³Health Alliance Medical Plans, Urbana, IL, USA

PDB57	MEDICATION NONADHERENCE AND POTENTIALLY AVOIDABLE HOSPITALIZATIONS AMONG PATIENTS WITH DIABETES
	Thumula V, Yang Y, Pace PF, Banahan BF, Wilkin NE, Lobb WB
	University of Mississippi, University, MS, USA

PDB58	NONADHERENCE TO ORAL HYPOGLYCEMIC AGENTS AND POTENTIALLY AVOIDABLE HOSPITALIZATIONS: AN EXAMINATION OF THE MEDICARE PART D PATIENTS WITH DIABETES
	Yang Y, Thumula V, Pace PF, Banahan BF, Wilkin NE, Lobb WB
	University of Mississippi, University, MS, USA

PDB59	EFFECT OF CAPITATED MEDICAID HEALTH PLANS ON MEDICATION ADHERENCE AND HEALTH CARE SERVICE UTILIZATIONS IN TYPE-2 DIABETES
	Pawaskar MD¹, Burch SP², Balkrishnan R³
	¹Ohio State University College of Pharmacy, Columbus, OH, USA, ²GlaxoSmithKline, Research Triangle Park, NC, USA, ³Ohio State University, Columbus, OH, USA

PDB60	ASSESSMENT OF THE INTERVAL BETWEEN FIRST EXENATIDE CLAIM AND LAST PRIOR ORAL ANTIDIABETIC CLAIM
	Misurski D¹, Quimbo RA², Hou L², Pawaskar MD¹, Wade R³
	¹Eli Lilly and Company, Indianapolis, IN, USA, ²HealthCore, Inc., Wilmington, DE, USA, ³HealthCore, Inc., Wilmington, DC, USA

PDB61	HEALTH CARE COSTS AND UTILIZATION ASSOCIATED WITH TREATMENT MODIFICATION IN TYPE-2 DIABETES MELLITUS (T2DM) PATIENTS TAKING ORAL ANTI-DIABETIC DRUGS (OADS)
	Krishnarajah G¹, Bhosle MJ², Chapman R²
	¹Bristol-Myers Squibb, Princeton, NJ, USA, ²IMS Health, Falls Church, VA, USA

PDB62	THE IMPACT OF PHARMACISTS INTERVENTIONS ON OUTCOMES OF DIABETIC PATIENTS COMPARED TO USUAL CARE
	Johnson KA, Chen S, Cheng IN, Lou M, McCombs JS
	University of Southern California, Los Angeles, CA, USA

PDB63	THE IMPACT OF A PPO PAY-FOR-PERFORMANCE PROGRAM ON DIABETIC PATIENTS
	Chen JY¹, Tian H¹, Hodges K², Juarez D³, Chung R⁴
	¹Health Benchmarks, Inc., Woodland Hills, CA, USA, ²Hawaii Medical Service Assocation, Honolulu, HI, USA, ³Hawaii Medical Service Association, Honolulu, HI, USA, ⁴HMSA, Honolulu, HI, USA

PDB64	A REVIEW OF RETROSPECTIVE, CONTINUOUS GLUCOSE MONITORING: AN EXAMPLE OF A MEDICAL DEVICE WHERE THE TYPICAL PRIMARY OUTCOME MEASURE MAY BE INAPPROPRIATE?
	Currie CJ¹, Poole CD², Papo NL³
	¹Cardiff University, Cardiff, UK, ²Pharmatelligence, Cardiff, South Glamorgan, UK, ³Medtronic International, Tolochenaz, Switzerland

PDB65	ASSOCIATIONS BETWEEN PATIENT-REPORTED DIABETES KNOWLEDGE AND HEALTH OUTCOMES, SELF-CARE, AND PREFERENCES FOR POTENTIALLY-BENEFICIAL NEW TREATMENT OPTIONS
	Bruhn D¹, Polonsky WH², Hawkins S³, Spollett G⁴, Joy S⁵, Uplinger N⁶, Sesetyan T³, Best JH⁷
	¹Eli Lilly and Company, Indianapolis, IN, USA, ²Behavioral Diabetes Institute, San Diego, CA, USA, ³Harris Interactive, Claremont, CA, USA, ⁴Albert Einstein Healthcare Network, New Haven, CT, USA, ⁵Duke University Medical Center, Durham, NC, USA, ⁶Albert Einstein Healthcare Network, Philadelphia, PA, USA, ⁷Amylin Pharmaceuticals, Inc., San Diego, CA, USA

POSTER PRESENTATIONS SESSION II
SET-UP:	Tuesday May 19, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Tuesday May 19, 2009 - 8:00AM-7:30PM
POSTER AUTHOR DISCUSSION HOUR:	Tuesday May 19, 2009 - 6:00PM-7:00PM
DISMANTLE:	Tuesday May 19, 2009 - 7:30PM-8:00PM

INFECTION Clinical Outcomes Studies
PIN1	STATISTICAL ANALYSIS OF MONONUCLEOSIS IN ADOLESCENTS
	LaRue CL
	University of Louisville, Louisville, KY, USA

PIN2	FACTORS INFLUENCING PEDIATRIC PATIENTS WITH PNEUMONIA
	Fleenor AL
	University of Louisville, Louisville, KY, USA

PIN3	WITHDRAWN



PIN4	US HEPATITIS-C BURDEN ASSESSMENT FROM A TRANSMISSION MODEL
	Zhang H, Mehra M, Dibello J
	Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA

PIN5	PHARMACOGENOMICS: APPLICABILITY IN ANTIRETRO VIRAL THERAPY (ART) IN HIV PATIENTS
	Goyal R¹, Rai MK¹, Chawla A², Siddiqui MK², Srivastava K²
	¹Heron Health Private Limited, Plot No 22-23, Rajiv Gandhi IT Park, Chandigarh, India, ²Heron Health Private Limited, Chandigarh, India

PIN6	A DATA ANALYSIS OF INPATIENTS AFFECTED BY THE HUMAN PAPILLOMAVIRUS
	Peercy DP
	University of Louisville, Louisville, KY, USA

PIN7	EXPLORING CELLULITIS: WHO GETS IT AND HOW SERIOUS IS IT?
	DeWilde KM
	University of Louisville, Louisville, KY, USA

INFECTION Cost Studies
PIN8	THE ECONOMIC IMPACT OF TRANSITIONING VALACYCLOVIR TO OVER THE COUNTER STATUS FOR THE TREATMENT OF GENITAL HERPES
	Chang JY, Nichol MB
	University of Southern California, Los Angeles, CA, USA

PIN9	INCREASING THE AVAILABILITY OF ATAZANAVIR IN THE MINISTRY OF HEALTH (MOH) PUBLIC INSTITUTIONS IN MEXICO: A BUDGET IMPACT ANALYSIS
	Uc-Coyoc R¹, Juarez-Garcia A¹, Rangel S¹, Villasis-Keever A², Elias-Lopez JI¹, Litalien G³, Donato B³
	¹Bristol-Myers Squibb, México City, Mexico, ²Bristol-Myers Squibb, Mexico City, Mexico, ³Bristol-Myers Squibb Pharmaceutical, Wallingford, CT, USA

PIN10	BUDGET IMPACT OF ANTIMALARIA DRUG FORMULARY DECISIONS: A RETROSPECTIVE ANALYSIS FROM A NIGERIAN TEACHING HOSPITAL
	Udezi WA¹, Usifoh CO¹, Omotayo OA²
	¹University of Benin, Benin, Edo, Nigeria, ²Faculty of Pharmacy, University of Benin, Benin, Edo, Nigeria

PIN11	MODELING THE INPATIENT AND OUTPATIENT COSTS OF METHICILLIN-RESISTANT STAPHYLOCCOCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI): A COMPARISON OF LINEZOLID, VANCOMYCIN, DAPTOMYCIN, AND TIGECYCLINE
	Stephens JM¹, Gao X¹, Verheggen BG², Shelbaya A³, Haider S⁴
	¹PharMerit North America LLC, Bethesda, MD, USA, ²PharMerit Europe, Rotterdam, Netherlands, ³Pfizer, New York, NY, USA, ⁴Pfizer, Groton, CT, USA

PIN12	COST-EFFECTIVENESS ANALYSIS OF DAPTOMYCIN VERSUS VANCOMYCIN IN COMPLICATED SKIN AND SOFT STRUCTURE INFECTION (CSSSI) USING A DECISION ANALYTIC MODEL
	Zargarzadeh A¹, Bounthavong M², Hsu D¹, Okamoto MP³
	¹Western University of Health Sciences, College of Pharmacy, Pomona, CA, USA, ²Veterans Affairs San Diego Healthcare System (VASDHS), San Diego, CA, USA, ³University of Hawaii at Hilo, College of Pharmacy, Hilo, HI, USA

PIN13	COMPARATIVE COST-EFFICACY ANALYSIS OF DARUNAVIR/R FOR FIRST-LINE TREATMENT OF HIV INFECTION IN THE UNITED STATES
	Soorapanth S¹, Brogan A¹, Mrus J², Smets E³
	¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Tibotec Therapeutics, Bridgewater, NJ, USA, ³Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium

PIN14	THE COST-EFFECTIVENESS OF TRUVADA, KIVEXA AND COMBIVIR IN THE TREATMENT OF ANTIRETROVIRAL NAïVE HIV-1 INFECTED PATIENTS IN MEXICO
	Rely K¹, Pierre KA², Salinas EG³
	¹Network on the Economic Evaluation of Healthcare Programmes and its Applications to Decision Making in Latin American Countries, Mexico, DF, Mexico, ²Johns Hopkins University, Bloomberg School of Public Health, Baltimore , MD, MD, USA, ³Hospital Infantil de México Federico Gómez, Mexico, DF, Mexico
PIN15	COMPARING COST-EFFECTIVENESS OF THE THREE- VERSUS TWO-DOSE VACCINATION PROTOCOL AGAINST HEPATITIS B IN ADOLESCENTS
	Hajarizadeh B¹, Rashidian A¹, Haghdoost AA², Alavian SM³
	¹Tehran University of Medical Sciences, Tehran, Tehran, Iran, ²Kerman University of Medical Sciences, Kerman, Kerman, Iran, ³Baqyatallah Research Center for Gastroenterology and Liver Diseases, Tehran, Tehran, Iran

PIN16	COST-EFFECTIVENESS ANALYSIS OF POSACONAZOLE FOR PROPHYLAXIS IN PATIENTS WITH NEUTROPENIA IN SOUTH KOREA
	Kim Y¹, Lee D², Jun S³, Jo C⁴, Lee S³, Kim B¹
	¹Seoul National University, Seoul, South Korea, ²Catholic University, Seoul, South Korea, ³Korea Institute of Environment and Health, Seoul, South Korea, ⁴Hallym University, Chuncheon, South Korea

PIN17	COST EFFECTIVE FOR HPV VACCINE
	Cheng IN, Hay JW
	University of Southern California, Los Angeles, CA, USA

PIN18	THE ESTABLISHMENT OF A COST-EFFECTIVE ANTIBIOTIC TREATMENT OF INFECTIVE ENDOCARDITIS AND MRSA BACTEREMIA IN MEXICAN PUBLIC HEALTH CARE SYSTEM
	Baca-Muro VI¹, Soria-Cedillo IF², Jirash J³, Olvera K³, De la Mora-Chávez T⁴, Garcia-Contreras F⁴
	¹Research Consulting, Puebla, Puebla, Mexico, ²Research Consulting, Hacienda Ojo de Agua, State of Mexico, Mexico, ³Novartis Farmaceutica Mexico, Mexico City, Mexico City, Mexico, ⁴Instituto Mexicano del Seguro Social, Mexico City, Mexico

PIN19	CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF A POLYMYXIN B-IMMOBILIZED HEMOPERFUSION CARTAGE FOR THE TREATMENT OF SEVERE SEPSIS: A SYSTEMIC REVIEW AND ECONOMIC EVALUATION
	Lee TJ¹, Lee H², Park B¹
	¹Seoul National University, Seoul, South Korea, ²Seoul National University, Seoul, Seoul, South Korea

PIN20	COST-EFFECTIVENESS OF PNEUMOCOCCAL POLYSACCHARIDE VACCINATION IN ADULTS: A SYSTEMATIC REVIEW OF CONCLUSIONS AND ASSUMPTIONS
	Ogilvie IM¹, El Khoury A², Cui Y², Dasbach E², Grabenstein J², Goetghebeur MM³
	¹BioMedCom Inc, Montreal, QC, Canada, ²Merck & Co., Inc., West Point, PA, USA, ³BioMedCom Consultants Inc, Montreal, QC, Canada

PIN21	VARIATION IN EFFICIENCY FRONTIERS FOR HIV/AIDS PREVENTION AND TREATMENT
	Kamae M¹, Kamae I², Cohen JT¹, Neumann PJ¹
	¹Tufts-New England Medical Center, Boston, MA, USA, ²Keio University, Fujisawa, Kanagawa, Japan

PIN22	COST OF PNEUMOCOCCAL INFECTIONS AND COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL VACCINATION IN TURKEY
	Akin L¹, Kaya M¹, Altinel S², Pehlivan T², Durand L³, Tasset-Tisseau A⁴
	¹Hacettepe University, Ankara, Turkey, ²Sanofi Pasteur, Istanbul, Turkey, ³Sanofi Pasteur, Lyon cedex 07, France, ⁴Sanofi Pasteur, Lyon, France

PIN23	APPLYING THE EFFICIENCY FRONTIER IN PHARMACEUTICAL POLICY MAKING. A CASE STUDY IN TREATMENT RESISTANT HIV/AIDS PATIENTS IN THE GERMAN SETTING
	Annemans L¹, Hill A², Smets E³, Martin SC³
	¹University of Ghent, Brussels University, Ghent, Belgium, ²HIV Solutions, London, UK, ³Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium

PIN24	ECONOMIC ANALYSIS OF PNEUMOCOCCAL VACCINATION FOR THE ELDERLY IN TAIWAN
	Hsieh SC¹, Liou WS², Lee CF³
	¹National Taiwan University, College of Public Health, Taipei City, Taiwan, ²Medical Affair Bureau, MND, Taipei, Taiwan, ³Tri-Service General Hospital, Taipei, Taiwan

PIN25	WITHDRAWN



PIN26	COST MINIMIZATION ANALYSIS FOR GENERIC AND BRAND NAME ANTIBIOTICS
	Malhan S¹, Tulunay FC²
	¹Baskent University, Ankara, Turkey, ²Ankara University, Ankara, Turkey

PIN27	COST ANALYSIS OF THE MASS VACCINATION CAMPAIGN AGAINST HEPATITIS B IN ADOLESCENTS IN IRAN
	Hajarizadeh B¹, Rashidian A¹, Haghdoost AA², Alavian SM³
	¹Tehran University of Medical Sciences, Tehran, Tehran, Iran, ²Kerman University of Medical Sciences, Kerman, Kerman, Iran, ³Baqyatallah Research Center for Gastroenterology and Liver Diseases, Tehran, Tehran, Iran

PIN28	SAVING COSTS FROM INFLUENZA IMMUNIZATION AMONG YOUNG CHILDREN – LIVE ATTENUATED VS. INACTIVATED INFLUENZA VACCINATION
	Rousculp MD¹, Quon P², Belshe RB³, Woodward TC², Luce B², Mahadevia PJ¹
	¹MedImmune, Inc., Gaithersburg, MD, USA, ²United BioSource Corporation, Bethesda, MD, USA, ³Saint Louis University School of Medicine, Saint Louis, MO, USA

PIN29	INFLUENZA: THE DEMOGRAPHICS AND TIME SPENT IN HOSPITALS OF THOSE INFECTED
	Rosbottom D
	University of Louisville, Louisville, KY, USA

PIN30	ACUTE CARE COSTS OF GRAM-NEGATIVE PNEUMONIA IN THE UNITED STATES: A HEALTH CARE COST AND UTILIZATION PROJECT (HCUP) DATA ANALYSIS
	Lee WC¹, Smalarz A¹, Pashos CL¹, Pennie S², Wittrup-Jensen K³
	¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Abt Bio-Pharma Solutions, Inc., Bethesda, MD, USA, ³Bayer Healthcare AG, Berlin, Germay, Germany

PIN31	THE ECONOMICS AND EPIDEMIOLOGY OF MENINGOCOCCAL INFECTION: A SYSTEMATIC LITERATURE REVIEW
	Whitesell E¹, Yaskin J¹, Chaudhari P²
	¹Jefferson School of Population Health, Philadelphia, PA, USA, ²Thomas Jefferson University, Philadelphia, PA, USA

PIN32	PHARMACOECONOMIC RELEVANCE OF ANTI-RETRO VIRAL THERAPY (ART) IN LOW AND MIDDLE INCOME COUNTRIES
	Rai MK¹, Goyal R¹, Srivastava K², Siddiqui MK², Chawla A², Joshi B³, Sehgal M²
	¹Heron Health Private Limited, Plot No 22-23, Rajiv Gandhi IT Park, Chandigarh, India, ²Heron Health Private Limited, Chandigarh, India, ³Heron Health Private Limited, Plot No. 22-23, Rajiv Gandhi IT Park, Chandigarh, India

PIN33	COST EFFECTIVENESS OF SWITCHING TO SECOND LINE THERAPY WITH LOPINAVIR/RITONAVIR (LPV/R) IN KENYA
	Simpson KN¹, Dietz B², Rahim S³, Rajagopalan R³
	¹Medical University of South Carolina, Charleston, SC, USA, ²Abbott GmbH & Co., Ludwigshafen, Germany, ³Abbott Laboratories, Abbott Park, IL, USA

PIN34	DOES COMBINING ANTIRETROVIRAL AGENTS IN TO A SINGLE DOSAGE FORM (CO-FORMULATIONS) ENHANCE QUALITY OF LIFE OF HIV/AIDS PATIENTS - A COST UTILITY STUDY
	Ganguli A, Wang J, Gourley D
	University of Tennessee Health Science Center, Memphis, TN, USA

PIN35	COST-EFFECTIVENESS OF MARAVIROC FOR HIV IN MEXICO
	Contreras-Hernandez I¹, Becker DL², Chancellor JV³, Kühne F⁴, Mould-Quevedo J⁵, Marfatia S⁶
	¹Social Security Mexican Institute, Mexico City, Mexico, ²i3 Innovus, Burlington, ON, Canada, ³i3 Innovus, Uxbridge, Middlesex, UK, ⁴i3 Innovus, Uxbridge, UK, ⁵Pfizer Mexico, Mexico City, Mexico, ⁶Pfizer, New York, NY, USA

PIN36	THE ECONOMIC IMPACT OF MARAVIROC FOR ANTIRETROVIRAL TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS IN MEXICO
	Contreras-Hernandez I¹, Rely K², Mould-Quevedo J³, Davila-Loaiza G³
	¹Social Security Mexican Institute, Mexico City, Mexico, ²Pharmacoeconomic Consultor, Mexico City, Mexico, ³Pfizer Mexico, Mexico City, Mexico
INFECTION Patient-Reported Outcomes Studies
PIN37	SELF-REPORTED PILL BURDEN AS A PREDICTOR FOR ADHERENCE IN HIV-INFECTED PATIENTS
	Wagner S¹, Gupta S², Waterman F³, Zoe-Powers A⁴, Oza D⁵, Grimm K⁵, Kim E⁵
	¹Consumer Health Sciences International, Princeton, NJ, USA, ²Consumer Health Sciences, Princeton, NJ, USA, ³Consumer Health Sciences, New York, NY, USA, ⁴Bristol-Myers Squibb, Mahwah, NJ, USA, ⁵Bristol-Myers Squibb, Plainsboro, NJ, USA

PIN38	PATIENT PREFERENCES AND STATED ADHERENCE FOR HEPATITIS C VIRUS TREATMENTS
	Mohamed AF¹, Hauber AB¹, Medjedovic J², Beam C³
	¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Novartis Pharma AG, Basel, Switzerland, ³Human Genome Sciences, Inc, Rockville, MD, USA

PIN39	ASSESSING DISEASE BURDEN FOR MEASLES USING A CLINICAL AND HEALTH OUTCOMES APPROACH: A FOCUS ON LOWER-INCOME COUNTRIES
	Bresnahan B¹, Babigumira JB¹, Veenstra DL¹, Bauch CT², Garrison L¹
	¹University of Washington, Seattle, WA, USA, ²University of Guelph, Guelph, ON, Canada

PIN40	WITHDRAWN

PIN41	WITHDRAWN

PIN42	ANALYZING INPATIENT DATA FOR HEPATITIS PATIENTS
	Sanders J
	University of Louisville, Louisville, KY, USA

PIN43	THE IMPACT OF ADVERSE DRUG REACTIONS ASSOCIATED WITH ANTI-TUBERCULOSIS MEDICATIONS ON HEALTH-RELATED QUALITY OF LIFE: A LONGITUDINAL ANALYSIS
	Guo N¹, Marra F², FitzGerald JM³, Elwood RK⁴, Marra CA¹
	¹University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³The Lung Centre, Vancouver General Hospital, Vancouver, BC, Canada, ⁴British Columbia Center for Disease Control, Vancouver, BC, Canada

PIN44	IDENTIFYING PREDICTORS OF HIV PATIENTS' SATISFACTION WITH MAIL-ORDER AND COMMUNITY PHARMACY SERVICES
	Ramasamy A, Pinto SL, Sahloff EG
	University of Toledo, Toledo, OH, USA

PIN45	EMPLOYEES' WILLINGNESS TO PAY FOR INFLUENZA VACCINATION OF HOUSEHOLD MEMBERS– RESULTS FROM THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF) STUDY
	Rousculp MD¹, Palmer L², Johnston S³, Mahadevia PJ¹, Nichol KL⁴
	¹MedImmune, Inc., Gaithersburg, MD, USA, ²Thomson Reuters, Ann Arbor, MI, USA, ³Thomson Healthcare, Inc, Washington, DC, USA, ⁴Veterans Affairs Medical Center, Minneapolis, MN, USA

INFECTIONHealth Care Use & Policy Studies
PIN46	EVALUATING SOCIETAL PREFERENCES FOR THE HUMAN PAPILLOMAVIRUS VACCINES USING DISCRETE CHOICE EXPERIMENT
	Oteng B¹, Marra CA¹, Lynd LD¹, Marra F²
	¹University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, VAncouver, BC, Canada

PIN47	IMPROVING PHYSICIAN ADHERENCE TO GUIDELINES FOR DRUG THERAPY: A RANDOMIZED CONTROLLED TRIAL OF EDUCATIONAL INTERVENTIONS IN A MANAGED CARE SETTING IN ISRAEL
	Kahan NR¹, Kahan E², Waitman DA¹, Vardy DA¹, Kitai E¹, Chinitz DP³
	¹Leumit Health Fund, Tel-Aviv, Israel, ²Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³The Hebrew University of Jerusalem School of Public Health, Jerusalem, Israel

PIN48	RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS, DENIALS, AND HOSPITALIZATIONS IN A COMMERCIALLY INSURED POPULATION
	Bowen KL¹, Jay M²
	¹Excellus BlueCross BlueShield, Rochester, NY, USA, ²Excellus BlueCross BlueShield, Williamsville, NY, USA

PIN49	NEW ANTIFUNGAL MEDICATION IMPACT ON MARKET SHARE AND UTILIZATION OF TRADITIONAL AGENTS IN A SINGLE HEALTH CARE SYSTEM
	Cavanaugh TM¹, Guo JJ², Martin-Boone JE¹, Enzweiler K³, Dusing-Wiest M³
	¹College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA, ²University of Cincinnati, Cincinnati, OH, USA, ³The Health Alliance, Cincinnati, OH, USA

PIN50	DRUG UTILIZATION REVIEW OF ANTIMICROBIAL DRUGS IN AN OUTPATIENT PRIVATE PEDIATRIC SETTING
	Gupta AS¹, Gupta G², Tiwari P³
	¹National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India, ²Charak Clinic, Mohali, Punjab, India, ³NIPER, Mohali, Punjab, India

PIN51	HOSPITAL LENGTH OF STAY AND COSTS ASSOCIATED WITH INAPPROPRIATE TREATMENT OF CANDIDEMIA IN THE ICU
	Zilberberg M¹, Kothari S², Arnold H³, Micek S⁴, Shorr AF⁵, Labelle A³, Kollef M³
	¹EviMed Research Group, LLC, Goshen, MA, USA, ²Astellas Pharma US, Inc., Deerfield, IL, USA, ³Barnes Jewish Hospital, St. Louis, MO, USA, ⁴Barnes Jewish Hospital, Ballwin, MO, USA, ⁵Washington Hospital Center, Washington, DC, USA

PIN52	WITHDRAWN

PIN53	HEALTH CARE UTILIZATION OF ANTIBIOTICS WITHIN THE SLOVAK REPUBLIC
	Tesar T, Foltan V, Binder R
	Comenius University, Bratislava, Slovak Republic

PIN54	INCREASING CHC TREATMENT RATE IN US IS A COST-SAVING STRATEGY
	Zhang H, Mehra M, Dibello J
	Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA

PIN55	VALIDATING LIKERT-TYPE MEASURES USING NONPARAMETRIC AND PARAMETRIC ITEM RESPONSE THEORY
	Lin HW¹, Pickard AS², Karabatsos G³, Mahady GB², Crawford SY², Popovich NG²
	¹China Medical University, Taichung, Taiwan, ²College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, ³College of Education, University of Illinois at Chicago, Chicago, IL, USA

PIN56	WITHDRAWN

PIN57	FACTORS AFFECTING CHOICE OF ANTIBIOTIC USE IN ACUTE BACTERIAL RESPIRATORY TRACT INFECTIONS: A SURVEY IN THAI PHYSICIANS
	Piyavetvirat K¹, Leartsakulpanitch J²
	¹Phramongkutklao Hospital, Bangkok, Thailand, ²Pfizer (Thailand) Ltd, Bangkok, Thailand

PIN58	DRUG UTILIZATION PATTERNS AND COSTS OF ANTIBIOTIC THERAPY AMONG PATIENTS WITH OR WITHOUT CANCER IN A 2000-BED MEDICAL CENTER IN TAIWAN
	Lin HW, Yao SH, Huang HC
	China Medical University, Taichung, Taiwan

POSTER PRESENTATIONS SESSION II
SET-UP:	Tuesday May 19, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Tuesday May 19, 2009 - 8:00AM-7:30PM
POSTER AUTHOR DISCUSSION HOUR:	Tuesday May 19, 2009 - 6:00PM-7:00PM
DISMANTLE:	Tuesday May 19, 2009 - 7:30PM-8:00PM

RESPIRATORY-RELATED DISORDERS Clinical Outcomes Studies
PRS1	SMOKING CESSATION AND ITS PREDICTORS: RESULTS FROM COMMUNITY BASED PHARMACY TOBACCO CESSATION PROGRAM IN NEW MEXICO
	Khan N¹, Du J¹, Anderson J², Tinker D³
	¹University of New Mexico, Albuquerque, NM, USA, ²University of New Mexcio, Albuquerque, NM, USA, ³New Mexico Pharmacists Association, Albuquerque, NM, USA

PRS2	DOES ADD-ON EVENING DOSE OF FORMOTEROL IMPROVE LUNG FUNCTION FOR COPD PATIENTS RECEIVING FIXED-DOSE OF TIOTROPIUM AND FORMOTEROL?
	Imran M, Kotwani A, Chhabra S, Vijayan V
	V.P. Chest Institute, Delhi, India

PRS3	COMPARATIVE EFFECTIVENESS OF IPRATROPIUM IN COPD PATIENTS
	Lee TA¹, Wilke CT², Joo M³, Stroupe KT⁴, Krishnan JA⁵, Schumock GT², Pickard AS⁶
	¹Hines VA Hospital and Northwestern University, Chicago, IL, USA, ²University of Illinois at Chicago, Chicago, IL, USA, ³Hines VA Hospital and University of Illinois at Chicago, Chicago, IL, USA, ⁴Midwest Center for Health Services & Policy Research, Hines, IL, USA, ⁵University of Chicago, Chicago, IL, USA, ⁶College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA

PRS4	DRUG UTILIZATION AND SPENDING TRENDS FOR ANTI-ASTHMATIC AGENTS IN US MEDICAID PROGRAM FROM 1991 TO 2007
	Chiu SF, Guo JJ, Wigle PR, Lin AC
	University of Cincinnati, Cincinnati, OH, USA

PRS5	WITHDRAWN

PRS6	ESTIMATION OF QUALITY-ADJUSTED LIFE EXPECTANCY AND LOSS OF UTILITY IN PATIENTS UNDER PROLONGED MECHANICAL VENTILATION
	Hung MC¹, Yan YH², Fan PS³, Lin MS³, Chen CR³, Wang JD¹
	¹National Taiwan University Hospital, Taipei, Taiwan, ²Chia-Yi Christian Hospital, Chiayi City, Taiwan, ³Chia-Yi Christian Hospital, Chiayi, Taiwan

RESPIRATORY-RELATED DISORDERS Cost Studies
PRS7	IMPACT OF STATIN THERAPY ON ASTHMA-RELATED EVENT COSTS IN ADULT ASTHMA PATIENTS
	Stanek EJ¹, Aubert RE¹, Xia F¹, Frueh FW², Sanders C², Weiss ST³, Epstein RS¹
	¹Medco Health Solutions, Inc., Franklin Lakes, NJ, USA, ²Medco Health Solutions, Inc., Bethesda, MD, USA, ³Channing Laboratory, Brigham and Womens Hospital, Boston, MA, USA

PRS8	COSTS OF SMOKING IN SLOVAKIA FROM A PAYER PERSPECTIVE
	Bielik J¹, Tomek D², Visnansky M³, Foltán V⁴, Mesaros S⁵, Szilagyiova P⁵
	¹Trencin University, Trencin, Slovak Republic, ²Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, ³General Health Insurance Company, Bratislava, Slovak Republic, ⁴Comenius University, Bratislava, Slovak Republic, ⁵Pfizer Slovakia, Bratislava, Slovak Republic

PRS9	MANAGED-CARE BUDGET IMPACT OF OMALIZUMAB FOR MODERATE TO SEVERE PERSISTENT ASTHMA
	Turpcu A¹, Leung G², Yim YM², Sapra S²
	¹University of Southern California, Los Angeles, CA, USA, ²Genentech, Inc., South San Francisco, CA, USA

PRS10	RETURN ON INVESTMENT FROM SMOKING CESSATION INSURANCE COVERAGE IN THE WORKPLACE: A CANADIAN EMPLOYER'S PERSPECTIVE
	Haycox A¹, Raymond V², Mills T³, Evans K³
	¹University of Liverpool Management School, Liverpool, UK, ²Pfizer Canada Inc, Kirkland, QC, Canada, ³Wolters Kluwer Health, Chester, UK

PRS11	QUANTIFYING COSTS AND BENEFITS OF TIMING PHARMACEUTICAL INTERVENTION: AN ECONOMIC SIMULATION MODEL OF ASTHMA IN ALBERTA, CANADA
	Thanh NX¹, Ohinmaa A², Mayers I², Yim R¹, Jacobs P¹
	¹Institute of Health Economics, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada

PRS12	ALLERGY IMMUNOTHERAPY CONFERS SIGNIFICANT HEALTH CARE COST SAVINGS WITHIN 3 MONTHS OF INITIATION: A MATCHED RETROSPECTIVE COHORT STUDY OF MEDICAID-ENROLLED CHILDREN NEWLY DIAGNOSED WITH ALLERGIC RHINITIS
	Hankin CS¹, Cox L², Leatherman B³, Lang D⁴, Gross G⁵, Fass P⁶, Bronstone A¹, Wang Z¹
	¹BioMedEcon, LLC, Moss Beach, CA, USA, ²University of Miami, Ft. Lauderdale, FL, USA, ³University of Arkansas for Medical Sciences, Little Rock, AR, USA, ⁴Cleveland Clinic, Cleveland, OH, USA, ⁵Dallas Allergy and Asthma Center, Dallas, TX, USA, ⁶Private Practice, Aventura, FL, USA

PRS13	THE IMPACT OF ASTHMA ON LOSS OF PRODUCTIVITY AND MEDICAL COSTS
	Song X¹, Costa LA², Anderson JA³, Shenolikar RA⁴
	¹Thomson Reuters, Cambridge, MA, USA, ²Laurie A. Costa, Inc, Bolton, MA, USA, ³Thomson Reuters, Ann Arbor, MI, USA, ⁴GlaxoSmithKline, Durham, NC, USA

PRS14	ANALYSIS OF OUTCOMES AND COSTS FOR PERSISTENT ASTHMA PATIENTS TREATED WITH BECLOMETHASONE DIPROPIONATE OR FLUTICASONE PROPIONATE
	Gross G¹, Lage MJ², Brewster C³, Spalitto A³
	¹Dallas Allergy and Asthma Center, Dallas, TX, USA, ²HealthMetrics Outcomes Research, LLC, Groton, CT, USA, ³Teva Specialty Pharmaceuticals, Kansas City, MO, USA

PRS15	SIMULATING COST-EFFECTIVENESS OF STEPPED CARE VERSUS REPEAT CARE IN SMOKING CESSATION
	Franklin BE, Klesges R
	University of Tennessee Health Science Center, Memphis, TN, USA

PRS16	AN ECONOMIC EVALUATION OF A PHARMACOLOGICAL INTERVENTION USING VARENICLINE AS THERAPY FOR SMOKING CESSATION
	Narváez J¹, Alvis N², de La Hoz F¹, Orozco J³, Porras A¹
	¹Universidad Nacional de Colombia, Bogotá D.C, Colombia, ²Universidad de Cartagena, Cartagena, Colombia, ³AYGES Consultoría S.A, Cartagena, Colombia

PRS17	A COST-CONSEQUENCE ANALYSIS COMPARING AN ESTABLISHED AND A NOVEL EPINEPHRINE AUTO-INJECTOR FOR ANAPHYLAXIS
	Desai U, Carroll NV
	Virginia Commonwealth University, Richmond, VA, USA

PRS18	THE ECONOMIC BURDEN OF CHRONIC OBSTRUCTION PULMONARY DISEASE DUE TO SMOKING
	Chang Y¹, Lee T²
	¹Northwestern University, Chicago, IL, USA, ²University of Illinois, Chicago, IL, USA

PRS19	HOW MUCH WOULD AMERICA SAVE IF ASTHMA DID NOT EXIST?
	Link SB, Nurmagambetov T
	Center for Disease Control and Prevention, Atlanta, GA, USA

PRS20	THE DIRECT ECONOMIC IMPACT OF EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): A REVIEW OF THE LITERATURE
	Toy EL¹, Gallagher KF¹, Stanley EL², Duh MS³
	¹Analysis Group, Inc., Lakewood, CO, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³Analysis Group, Inc., Boston, MA, USA

PRS21	THE WORKPLACE BURDEN OF SMOKING
	Mark TL¹, Johnston S¹, Cao Z²
	¹Thomson Healthcare, Inc, Washington, DC, USA, ²Thomson Healthcare, Inc, Cambridge, MA, USA

PRS22	IMPACT OF APPROPRIATE THERAPY ON ASTHMA-RELATED HEALTH CARE UTILIZATION AND EXPENDITURES IN A MEDICAL POPULATION OF SEVERE ASTHMATIC PATIENTS
	Ejzykowicz F, Johnson KA
	University of Southern California, Los Angeles, CA, USA

PRS23	COST AND RESOURCE UTILIZATION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) OR WINTER UNSPECIFIED BRONCHIOLITIS OR PNEUMONIA (UBP) HOSPITALIZATIONS DURING THE FIRST YEAR OF LIFE AMONG LATE PRETERM AND FULL-TERM INFANTS
	Forbes ML¹, Hall CB², Jackson A³, Masaquel A⁴, Mahadevia PJ⁴
	¹Akron Children's Hospital, Akron, OH, USA, ²University of Rochester Medical School, Rochester, NY, USA, ³Milliman, Inc, Indianapolis, IN, USA, ⁴MedImmune, Inc., Gaithersburg, MD, USA

PRS24	INCREMENTAL ASTHMA-RELATED EXPENDITURES ASSOCIATED WITH HIGH UTILIZATION OF SHORT ACTING ß-AGONISTS AMONG A COMMERCIALLY INSURED ASTHMATIC POPULATION IN THE U.S.
	Kamble S¹, Blanchette CM², Silver H², Petersen H², Meddis D³, Gutierrez B³
	¹University of North Carolina at Charlotte, Charlotte, NC, USA, ²Lovelace Respiratory Research Institute, Albuquerque, NM, USA, ³AstraZeneca, Wilmington, DE, USA

PRS25	THE FINANCIAL IMPACT OF COMPUTER SYSTEMS–BASED APPROACHES TO REDUCING REPEAT DRUG EXPOSURE IN PATIENTS WITH KNOWN DRUG ALLERGIES
	Huang YF¹, Lin YM², Liu HP², Chien HY²
	¹Taipei Medical University - Shuang Ho Hospital, Jhonghe, Taiwan, ²Taipei Medical University - Shuang Ho Hospital, Taipei, Taiwan

PRS26	AN ECONOMIC EVALUATION OF GRAZAX FOR THE TREATMENT OF GRASS POLLEN INDUCED RHINOCONJUNCTIVITIS IN CHILDREN
	Whitehead S¹, Taylor MJ¹, Christensen J²
	¹University of York, York, UK, ²ALK-Abelló, Hørsholm, Denmark

PRS27	ASTHMA-RELATED PRODUCTIVITY LOSSES IN ALBERTA, CANADA
	Thanh NX¹, Ohinmaa A², Yan C¹
	¹Institute of Health Economics, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada

PRS28	TRENDS IN PREVALENCE OF OBESITY AND MEDICAL COSTS IN ASTHMA PATIENTS IN THE UNITED STATES
	Choi IS¹, Noyes D¹, Kwon JW¹, Sohn HS², Suh K¹, Yang JH¹
	¹Rutgers University, Piscataway, NJ, USA, ²Sook Myung Women's University, Seoul, South Korea

RESPIRATORY-RELATED DISORDERS Patient-Reported Outcomes Studies
PRS29	CAN OLDER, CHRONICALLY ILL ADULTS USE ELECTRONIC DIARIES? COMPLIANCE RATES IN A PROSPECTIVE STUDY OF PATIENTS WITH COPD
	Cates C, Roberts L, Eremenco S, Wilcox TK, Leidy NK
	United BioSource Corporation, Bethesda, MD, USA

PRS30	MEDICATION NON-FULFILLMENT AND NON-PERSISTENCE AMONG 29,000 ADULTS WITH CHRONIC DISEASE: HOW OFTEN AND WHY
	Spain CV, McHorney CA
	Merck & Co., Inc., West Point, PA, USA

PRS31	ASSOCIATION BETWEEN COMPLIANCE AND RESPIRATORY-RELATED COSTS FOR PATIENTS WITH COPD TREATED WITH MAINTENANCE THERAPY
	Halpern R¹, Curtice TG², Marfatia A³, Woodruff KB³, Shah H²
	¹i3 Innovus, an Ingenix Company, Eden Prairie, MN, USA, ²Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA, ³Pfizer, New York, NY, USA

PRS32	ADJUSTING THE NICOTINE DOSE: THE KEY TO A SUCCESSFUL, “TAILORED” METHOD OF QUITTING SMOKING
	Taieb C
	Pierre Fabre, Boulogne, France

PRS33	MEASUREMENT OF QUALITY OF LIFE BY EQ-5D IN PROLONGED MECHANICAL VENTILATION PATIENTS: COMPARISON BETWEEN PATIENTS AND PROXIES
	Hung MC¹, Yan YH², Fan PS³, Lin MS³, Chen CR³, Wang JD¹
	¹National Taiwan University Hospital, Taipei, Taiwan, ²Chia-Yi Christian Hospital, Chiayi City, Taiwan, ³Chia-Yi Christian Hospital, Chiayi, Taiwan

PRS34	EQ-5D BASED QOL ASSESSMENT IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) IN JAPAN
	Igarashi A¹, Makita H², Fukuda T³, Akazawa M³, Kato Y³, Tsutani K¹, Nishimura M²
	¹University of Tokyo, Bunkyo, Tokyo, Japan, ²Hokkaido University School of Medicine, Sapporo, Hokkaido, Japan, ³University of Tokyo, Tokyo, Tokyo, Japan

RESPIRATORY-RELATED DISORDERSHealth Care Use & Policy Studies
PRS35	PREVALENCE OF ASTHMA, DIABETES MELLITUS AND ESSENTIAL HYPERTENSION AND ASSOCIATION OF HEALTH INSURANCE WITH BRAND STATUS OF DIAGNOSIS SPECIFIC PRESCRIPTION DRUGS
	Dalwadi RY, Dhing CW
	St. John's University, Jamaica, NY, USA

PRS36	HOSPITAL RESOURCE UTILIZATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE- AN ANALYSIS OF THE 2005 NATIONAL INPATIENT SAMPLE DATA
	Rane PB¹, Kamal KM², Keys PA², Giannetti VJ²
	¹West Virginia University, Morgantown, WV, USA, ²Duquesne University, Pittsburgh, PA, USA

PRS37	WHICH SMOKERnS GET ADVICE TO QUIT? VARIABLES ASSOCIATED WITH PHYSICIAN ADVICE FOR SMOKING CESSATION
	Gause D, Plauschinat CA
	Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PRS38	CONTINUOUS TREATMENT WITH FIXED COMBINATION OF LABA/ICS CAN AVOID COSTS OF HOSPITALIZATION IN ASTHMA AND COPD IN GERMANY
	Bonthapally V¹, Sindern J², Wolbring F², Mehnert A³
	¹University of Louisiana at Monroe, Monroe, LA, USA, ²Janssen-Cilag GmbH, Neuss, Germany, ³Janssen-Cilag GmbH, Neuss, NRW, Germany

PRS39	ADHERENCE AMONG COPD SUBJECTS ON TIOTROPIUM AND FLUTICASONE/SALMETEROL
	Halpern R¹, Marfatia A², Woodruff KB², Shah H³
	¹i3 Innovus, an Ingenix Company, Eden Prairie, MN, USA, ²Pfizer, New York, NY, USA, ³Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA

PRS40	MEDICATION USE AND ASTHMA CONTROL – ANALYZING ECONOMIC TRADEOFFS USING INSURANCE CLAIMS DATA
	Saha S, Nurmagambetov T
	Centers for Disease Control and Prevention, Atlanta, GA, USA

PRS41	APPROPRIATE USE OF INHALED CORTICOSTEROID AND LONG-ACTING ß-AGONIST COMBINATION THERAPY AMONG ASTHMA PATIENTS
	Blanchette CM¹, Culler S², Gutierrez B³
	¹Lovelace Respiratory Research Institute, Kannapolis, NM, USA, ²Emory University, Atlanta, GA, USA, ³AstraZeneca, Wilmington, DE, USA

PRS42	CURRENT PATTERNS OF FIXED AND FREE LABA/ICS COMBINATION USAGE IN ASTHMA SHI PATIENTS IN GERMANY
	Bonthapally V¹, Wolbring F², Sindern J², Mehnert A³
	¹University of Louisiana at Monroe, Monroe, LA, USA, ²Janssen-Cilag GmbH, Neuss, Germany, ³Janssen-Cilag GmbH, Neuss, NRW, Germany

PRS43	RACIAL DISPARITIES IN UTILIZATION OF ASTHMA CONTROLLER MEDICATIONS
	Vaidya V¹, Hufstader MA², Ganguli A¹
	¹University of Tennessee, Memphis, TN, USA, ²University of Tennessee Health Science Center, Memphis, TN, USA

PRS44	QUALITY OF LIFE EVALUATION OF PATIENTS WITH NON-TRANSMISSIBLE CHRONIC DISEASES ENROLLED IN A PHARMACY BENEFIT MANAGEMENT
	Reis Neto JP, Tovar C
	CAPESESP/CAPESAUDE, Rio de Janeiro, RJ, Brazil

PRS45	SMOKING-ATTRIBUTABLE BURDEN OF FOUR TOBACCO-RELATED DISEASES IN COLOMBIA IN 2007
	Narváez J¹, Alvis N², de La Hoz F¹, Orozco J³, Porras A¹
	¹Universidad Nacional de Colombia, Bogotá D.C, Colombia, ²Universidad de Cartagena, Cartagena, Colombia, ³AYGES Consultoría S.A, Cartagena, Colombia

PRS46	ASSESSING ASTHMA MANAGEMENT IN AN URBAN COMMUNITY IN DELHI, INDIA
	Kotwani A, Chhabra S, Vijayan V
	V.P. Chest Institute, Delhi, India

PRS47	DATA ANALYSIS TECHNIQUES APPLIED TO DISCOVER TRENDS AND PATTERNS IN PEDIATRIC ASTHMA
	Yadhati P, Cerrito PB
	University of Louisville, Louisville, KY, USA

POSTER PRESENTATIONS SESSION II
SET-UP:	Tuesday May 19, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Tuesday May 19, 2009 - 8:00AM-7:30PM
POSTER AUTHOR DISCUSSION HOUR:	Tuesday May 19, 2009 - 6:00PM-7:00PM
DISMANTLE:	Tuesday May 19, 2009 - 7:30PM-8:00PM

SYSTEMIC DISORDERS/CONDITIONS Clinical Outcomes Studies
PSY1	OXYCODONE-RELATED FATALITIES IN WEST VIRGINIA
	Peirce GL, Abate M, Smith MJ
	West Virginia University, Morgantown, WV, USA

PSY2	HOW WELL DOES BODY MASS INDEX PREDICT WAIST CIRCUMFERENCE FOR PATIENTS WITH METABOLIC SYNDROME?
	Liu G¹, Luo N², McCollam PL³, Xie Y⁴
	¹Peking University, Beijing, China, ²National University of Singapore, Singapore, Singapore, ³Eli Lilly and Company, Indianapolis, IN, USA, ⁴University of Iowa, Iowa City, IA, USA

PSY3	BURDEN OF OBESITY AND ASSOCIATED TREATMENT PATTERNS IN EUROPE: A COMPARISON OF FIVE COUNTRIES
	Narayanan S¹, Potthoff P², Guether B²
	¹TNS Healthcare, New York, NY, USA, ²TNS Healthcare, Munich, Bavaria, Germany

PSY4	THE USE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY DATA TO UNDERSTAND DIFFERENCES IN RECOMBINANT FACTOR VIIA (RFVIIA) DOSING AND CLINICAL OUTCOMES FOR SPECIFIC JOINT HEMORRHAGES IN HEMOPHILIA
	Valentino LA¹, Cooper DL²
	¹Rush University and Rush Children's Hospital, Chicago, IL, USA, ²Novo Nordisk, Inc., Princeton, NJ, USA

PSY5	THE USEFULNESS OF REGISTRY DATA FOR UNDERSTANDING TREATMENT PRACTICES AND CLINICAL OUTCOMES IN HEMOPHILIA: THE EXPERIENCE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY (2004-2008)
	Kessler CM¹, Gill JC², Cooper DL³
	¹Georgetown University Medical Center, Washington, DC, USA, ²Medical College of Wisconsin, Milwaukee, WI, USA, ³Novo Nordisk, Inc., Princeton, NJ, USA

PSY6	CONTRIBUTIONS OF THE HUNTER OUTCOME SURVEY (HOS) TO ADVANCING UNDERSTANDING OF HUNTER SYNDROME
	Muenzer J¹, Beck M², Giugliani R³, Hernberg-Ståhl E⁴, Wraith JE⁵
	¹University of North Carolina, Chapel Hill, NC, USA, ²University of Mainz, Mainz, Germany, ³Hospital de Clinicas/UFRGS, Porto Alegre, RS, Brazil, ⁴Shire Human Genetic Therapies, Danderyd, Sweden, ⁵Royal Manchester Children's Hospital, Manchester, UK

PSY7	DISEASE FLARES AMONG PATIENTS WITH CROHN'S DISEASE
	Waters HC¹, Bolge SC², Freedman D², Piech CT¹
	¹Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ²Consumer Health Sciences International, Princeton, NJ, USA

PSY8	IMPORTANCE OF ROUTINE URINE DRUG TESTING IN THE CHRONIC PAIN PATIENT POPULATION
	Couto JE¹, Leider HL², Romney M¹, Goldfarb NI¹
	¹Thomas Jefferson University, Philadelphia, PA, USA, ²Ameritox, Ltd, Baltimore, MD, USA

PSY9	USING UTILIZATION RECORDS TO ESTIMATE THE BURDEN OF OBESITY IN ADULTS LIVING IN ONTARIO
	Tarride JE, Haq M, O'Reilly D, Xie F, Bowen JM, Goeree R
	McMaster University, Hamilton, ON, Canada

PSY10	PREVALENCE OF METABOLIC SYNDROME AND DIFFERENCES IN HEALTH HABITS AMONG SUFFERERS AMONG U.S. ETHNIC GROUPS
	Kannan H, Wagner S, Bolge SC
	Consumer Health Sciences International, Princeton, NJ, USA

PSY11	ESTIMATION OF CAUSAL EFFECTS OF PHYSICAL ACTIVITY ON OBESITY BY A RECURSIVE BIVARIATE PROBIT MODEL
	Kawatkar AA, Nichol MB
	University of Southern California, Los Angeles, CA, USA

PSY12	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OR SEVERE ANEMIA: DATA FROM MULTI-CENTER CLINICAL PRACTICES
	Raptis A¹, Duh MS², Wang ST², Dial E², Fanourgiakis I¹, Fortner B³, Paley C⁴, Mody-Patel N⁴, Corral M⁴, Scott J⁵
	¹University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, ²Analysis Group, Inc., Boston, MA, USA, ³P4 Healthcare, Lakeland, TN, USA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ⁵P4 Healthcare, Ellicott City, MD, USA

PSY13	FREQUENCY AND BOTHERSOMENESS OF SIDE EFFECTS IN PAIN PATIENTS TAKING OXYCODONE IMMEDIATE RELEASE: IMPACT ON nPRESCRIPTION AND OVER-THE-COUNTER MEDICATION USE
	Anastassopoulos K¹, Chow W², Ackerman SJ³, Tapia CI³, Benson C², Kim M²
	¹Covance Market Access Services, Inc, Gaithersburg, MD, USA, ²Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, ³Covance Market Access Services, Inc, San Diego, CA, USA

PSY14	TOLERABILITY OF INTRAVENOUSLY ADMINISTERED IMMUNE GLOBULIN IN THE HOME SETTING
	Tankersley MA, D’Albini, LD, Steinberg, SC
	Accredo Therapeutics, a division of Accredo Health Group, Inc, Memphis, TN, USA

SYSTEMIC DISORDERS/CONDITIONS Cost Studies
PSY15	THE IMPACT OF ADHERENCE ON THE COSTS AND BENEFITS OF INTENSIVE LIFESTYLE MANAGEMENT (ILM) IN OVERWEIGHT AND OBESE PATIENTS AT HIGH RISK FOR TYPE-2 DIABETES MELLITUS (T2DM)
	Willis M¹, Asseburg C¹, He J², Neslusan C²
	¹IHE - The Swedish Institute for Health Economics, Lund, Sweden, ²Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA

PSY16	A CANADIAN BASED PHARMACOECONOMIC ANALYSIS OF SELECTED ANTICONVULSANTS, SNRIS AND TCAS IN TREATING NEUROPATHIC PAIN
	Iskedjian M, Walker J
	PharmIdeas Research and Consulting Inc, Oakville, ON, Canada

PSY17	DECISION-ANALYTIC MODELLING OF TREATMENT OPTIONS FOR PATIENTS WITH SEVERE HAEMOPHILIA A AND INHIBITORS IN GERMANY
	Eheberg D¹, Berger K², Schramm W³
	¹IMS Health GmbH & Co. OHG, Munich, Germany, ²University Hospital of Munich, Munich, Germany, ³University Hospital of Munich, München, Germany

PSY18	ECONOMIC EVALUATION OF AN INTERNET BASED WEIGHT MANAGEMENT PROGRAM
	Rasu R¹, Hunter C², Maruska H³, Peterson A⁴, Foreyt J⁵
	¹University of Missouri- Kansas City, Kansas City, MO, USA, ²National Institute of Diabetes & Digestive & Kidney Diseases, NIH, Bethesda, MD, USA, ³University of Missouri Kansas City School of Pharmacy, Kansas City, MO, USA, ⁴University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, ⁵Baylor College of Medicine, Houston, TX, USA

PSY19	COST-EFFECTIVENESS COMPARISON ANALYSIS OF ANTI-TNF AGENTS WITH MULTIPLE INDICATIONS
	Szkurhan AR
	Dymaxium Inc, Toronto, ON, Canada

PSY20	WITHDRAWN

PSY21	COST-EFFECTIVENESS OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA: A MEXICAN PERSPECTIVE
	Arreola-Ornelas H¹, Rosado-Buzzo AA², García-Mollinedo MDL², Dorantes-Aguilar J¹, Mould-Quevedo J³, Davila-Loaiza G³
	¹Fundación Mexicana para la Salud, Mexico City, Mexico, ²Links & Links S.A. de C. V, Mexico City, Mexico, ³Pfizer Mexico, Mexico City, Mexico

PSY22	ECONOMIC EVALUATION OF RECOMBINANT FACTOR VIII PRODUCTS IN TREATMENT OF HAEMOPHILIA A. IN KOREA
	Kim JY¹, Lee JH², Heo JH¹, Lee EK¹
	¹Sook Myung Women's University, Seoul, South Korea, ²Sook Myung Women's University, Seoul, Seoul, South Korea

PSY23	ECONOMIC EVALUATION OF DARBEPOETIN ALFA AND EPOETIN IN HEMODIALYSIS PATIENTS WITH ANEMIA AND CHRONIC KIDNEY DISEASE
	Vorobiev P¹, Lesnicheva M², Avksentieva M³, Nekrasova N¹
	¹Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia, ²Russian Society For Pharmacoeconomics and Outcomes Research, Moscow, Russia, ³Moscow Medical Academy named after I.M.Sechenov, Moscow, Moscow, Russia

PSY24	THE IMPACT OF OBESITY ON MEDICAL EXPENDITURE AND HEALTH RELATED QUALITY OF LIFE
	Kawatkar AA, Nichol MB
	University of Southern California, Los Angeles, CA, USA

PSY25	MEDICAL TREATMENT COSTS ATTRIBUTABLE TO OBESITY IN PATIENTS WITH ASTHMA AMONG U.S. ADULTS
	Suh DC¹, Yang JH¹, Kim CM², Jang SM³, Jung JC⁴, Barone JA¹
	¹Rutgers University, Piscataway, NJ, USA, ²Catholic University, Seoul, South Korea, ³Health Insurance Review & Assessment Service, Seoul, South Korea, ⁴Korea National Health Insurance Corporation, Mapo-gu, Seoul, South Korea

PSY26	COST OF OPIOID USE IN A COMMERCIALLY INSURED POPULATION OF FIBROMYALGIA PATIENTS
	Juday T, Blum S, Erder MH
	Forest Research Institute, Jersey City, NJ, USA

PSY27	THE LONG-TERM COST OF ORTHOPAEDIC SURGERY WITH RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) IN HAEMOPHILIA INHIBITnOR PATIENTS
	Ericsson Å, Haglund M
	Novo Nordisk Scandinavia AB, Malmo, Sweden

PSY28	ESTIMATE COSTS OF COMORBIDITES IN OVERWEIGHT AND OBESE MEXICAN CHILDREN AGED BETWEEN FIVE AND ELEVEN YEARS UNTIL DEATH
	Anaya P, Meléndez G
	Fundación Mexicana para la Salud, El Arenal Tepepan, D.F, Mexico

PSY29	VARIABILITY OF FEES IN THE FIELD OF HAEMOGRAMS IN THE AUSTRIAN CONTRACT PHYSICIANS' AND INSTITUTES' SECTOR
	Scholler C, Weisser A, Wilbacher I, Endel G
	Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria

PSY30	ECONOMIC BURDEN OF FIBROMYALGIA COMPARED TO OTHER CHRONIC CONDITIONS
	Blum S, Juday T, Erder MH
	Forest Research Institute, Jersey City, NJ, USA

PSY31	REAL-WORLD USE OF DULOXETINE FOR LOW BACK PAIN
	Ivanova J¹, Birnbaum HG², Schiller M², Kantor E², Waldman T², Johnstone BM³, Faries D⁴, Risser R⁴, Swindle R³
	¹Analysis Group, Inc., New York, NY, USA, ²Analysis Group, Inc., Boston, MA, USA, ³Eli Lilly and Company, Indianapolis, IN, USA, ⁴Lilly USA, LLC, Indianapolis, IN, USA

PSY32	HEALTH CARE UTILIZATION AND FACTOR COST IN HEMOPHILIA
	Zhou ZY¹, Globe D², Ullman M³, Baker J⁴, Koerper M⁵, Gwadry-Sridhar F⁶, Wu J¹, Forsberg A⁷, Shapiro A⁸, Trawinski B⁸, Duncan N⁸, Johnson KA¹
	¹University of Southern California, Los Angeles, CA, USA, ²Amgen, Thousand Oaks, CA, USA, ³Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA, ⁴University of California, Los Angeles, Los Angeles, CA, USA, ⁵University of California, San Francisco, San Francisco, CA, USA, ⁶University of Western Ontario, London, ON, Canada, ⁷New England Hemophilia Center, Worcester, MA, USA, ⁸Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA

PSY33	PROCESS MEASUREMENT AND CALCULATION IN IV-PCA AT UNIVERSITY HOSPITAL OULU FINLAND
	Liwing J¹, Rebmann I², Idänpään-Heikkilä JJ³, Löthgren M¹, Rahkamo L³, Kraemer M², Rautio P⁴, Salomäki T⁵
	¹Janssen-Cilag AB, Sollentuna, Sweden, ²Siemens AG Healthcare Consulting, Erlangen, Germany, ³Janssen-Cilag Oy, Espoo, Finland, ⁴Medicres Oy, Oulu, Finland, ⁵Oulu university hospital, Oulu, Finland

SYSTEMIC DISORDERS/CONDITIONSPatient-Reported Outcomes Studies
PSY34	IMPACT OF OBESITY ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ASTHMA IN THE USA
	Kwon JW¹, Suh K¹, Choi IS¹, Sohn HS², Nam EW¹, Barone JA¹
	¹Rutgers University, Piscataway, NJ, USA, ²Sook Myung Women's University, Seoul, South Korea

PSY35	THE RELATIONSHIP BETWEEN QUALITY OF LIFE, DISABILITY AND PAIN IN PATIENTS WITH FAILED BACK SURGERY SYNDROME
	Manca A¹, Eldabe S², Buchser E³, Kumar K⁴, Taylor R⁵
	¹University of York, York, UK, ²James Cook University Hospital, Middlesbrough, UK, ³EHC-Hospital of Morges, Morges, Switzerland, ⁴Clinical Professor of Neurosurgery, Regina, Saskatchewan, Canada, ⁵Universities of Exeter and Plymouth, Exeter, UK

PSY36	THE HEALTH BURDEN OF NEUROPATHIC PAIN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF HEALTH UTILITIES
	Taylor RS¹, Jensen M², Doth AH³
	¹Universities of Exeter and Plymouth, Exeter, UK, ²University of Washington School of Medicine, Seattle, WA, USA, ³Medtronic Neuromodulation, Minneapolis, MN, USA

PSY37	THE OBESITY TRENDS IN GENERAL POPULATION OF THE REPUBLIC OF SERBIA
	Tadic I¹, Tasic L¹, Djekic S², Rakic M³, Tasic D⁴
	¹University of Belgrade, Faculty of Pharmacy, Belgrade, Serbia and Montenegro, ²Velefarm A.D, Novi Sad, Serbia and Montenegro, ³Public Pharmacy NIS, NIS, Serbia and Montenegro, ⁴University of Utah, Salt Lake City, UT, USA

PSY38	VALIDATION OF THE TREATMENT RELATED IMPACT MEASURE FOR PRESCRIPTION WEIGHT LOSS MEDICATION IN OBESITY; TRIM-WEIGHT
	Brod M¹, Hammer M², Kragh N², Lessard S¹, Bushnell D³
	¹The BROD GROUP, Mill Valley, CA, USA, ²Novo Nordisk A/S, Bagsværd, Denmark, ³Health Research Associates, Inc., Mountlake Terrace, WA, USA

PSY39	LINGUISTIC VALIDATION OF THE LUPUS QOL QUESTIONNAIRE INTO 13 LANGUAGES
	Handa ML¹, McKown S¹, Gawlicki M²
	¹Corporate Translations, Inc, Chicago, IL, USA, ²Corporate Translations, Inc, East Hartford, CT, USA

PSY40	FEASIBILITY OF DAILY DIARIES WITH QOL ASSESSMENT IN CONGENTIAL HEMOPHILIA PATIENTS WITH ALLOANTIBODY INHIBITORS
	Wilke CT¹, Young GA², Cooper DL³, Pickard AS⁴
	¹University of Illinois at Chicago, Chicago, IL, USA, ²Children's Hospital of Los Angeles, Los Angeles, CA, USA, ³Novo Nordisk, Inc., Princeton, NJ, USA, ⁴College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA

PSY41	PATIENT-REPORTED OUTCOME (PRO) LABELING CLAIMS IN PAIN TREATMENT: OVERVIEW OF US AND EUROPEAN DRUG APPROVALS
	Caron M¹, Emery MP¹, Marquis P², Piault E², Scott JA³
	¹MAPI Research Trust, Lyon, France, ²Mapi Values, Boston, MA, USA, ³Mapi Values, Macclesfield, Cheshire, UK

PSY42	USTEKINUMAB REDUCES ITCH, BODILY PAIN, AND FATIGUE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
	Lebwohl M¹, Papp KA², Han C³, Schenkel B³, Yeilding N⁴, Wang Y⁴, Krueger GG⁵
	¹Mount Sinai School of Medicine, New York, NY, USA, ²Probity Medical Research, Waterloo, ON, Canada, ³Johnson & Johnson Pharmaceutical Services LLC, Malvern, PA, USA, ⁴Centocor Research and Development, Inc, Malvern, PA, USA, ⁵University of Utah Health Sciences Center, Salt Lake City, UT, USA

SYSTEMIC DISORDERS/CONDITIONSHealth Care Use & Policy Studies
PSY43	USE OF PRESCRIPTION PHARMACOTHERAPY IN PATIENTS WITH FIBROMYALGIA:EVIDENCE OF UNMET NEEDS?
	Berger A¹, Oster G¹, Juday T², Blum S², Erder MH²
	¹Policy Analysis Inc. (PAI), Brookline, MA, USA, ²Forest Research Institute, Jersey City, NJ, USA

PSY44	USE OF POLYPHARMACY IN PATIENTS WITH FIBROMYALGIA
	Berger A¹, Oster G¹, Juday T², Blum S², Erder MH²
	¹Policy Analysis Inc. (PAI), Brookline, MA, USA, ²Forest Research Institute, Jersey City, NJ, USA

PSY45	CURTAILING LAB-TEST ORDERING IN A MANAGED CARE SETTING THROUGH REDESIGN OF A COMPUTERIZED ORDER-FORM
	Kahan NR, Waitman DA, Vardy DA
	Leumit Health Fund, Tel-Aviv, Israel

PSY46	PATTERNS OF CARE IN THE PHARMACOLOGIC TREATMENT OF MODERATE-TO-SEVERE PSORIASIS
	Hankin CS¹, Lebwohl M², Knispel J³, Dunn JD⁴, Lopes M⁵, Bronstone A¹, Wang Z¹
	¹BioMedEcon, LLC, Moss Beach, CA, USA, ²Mount Sinai School of Medicine, New York, NY, USA, ³Humana, Singer Island, FL, USA, ⁴SelectHealth Plans, Salt Lake City, UT, USA, ⁵MMD Lopes, LLC, Cresskill, NJ, USA

PSY47	CROHN'S DISEASE TREATMENT PARADIGM
	Waters HC¹, Bolge SC², Freedman D², Piech CT¹
	¹Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ²Consumer Health Sciences International, Princeton, NJ, USA

PSY48	IMPACT OF DIFFERENT WEIGHT CONTROL MEASURES TAKEN BY THE STUDENTS ON THEIR WEIGHT
	Sreepada A
	University of Louisville, Louisville, KY, USA

PSY49	DETERMINANTS OF MEDICAL SERVICES UTILIZATION IN CHRONIC NONCANCER PAIN PATIENTS
	Puenpatom RA, Victor TW
	Endo Pharmaceuticals, Chadds Ford, PA, USA

PSY50	REVENUES FROM VENDED BEVERAGES IN WEST VIRGINIA PUBLIC SCHOOLS
	Blake KB¹, Harris CV¹, Bradlyn AS¹, Moore LC¹, Abildso L¹, Coffman J¹, O'Hara Tompkins N², Purkey M³, Chapman D³, Kennedy K⁴, Blower K⁴
	¹West Virginia University, Morgantown, WV, USA, ²West Virginia University, Charleston, WV, USA, ³West Virginia Department of Education, Charleston, WV, USA, ⁴West Virginia Department of Health and Human Resources, Charleston, WV, USA

PSY51	OBESITY AND MEDICARE EXPENDITURE: ACCOUNTING FOR AGE-RELATED HEIGHT LOSS
	Onwudiwe N¹, Stuart B², Zuckerman IH², Sorkin J³
	¹University of Maryland School of Pharmacy, SILVER SPRING, MD, USA, ²University of Maryland School of Pharmacy, Baltimore, MD, USA, ³University of Maryland School of Medicine Division of Gerontology, Baltimore, MD, USA

PSY52	ESTIMATION OF CLINICAL AND ECONOMIC IMPACT OF CHRONIC PAIN ON THE BENEFICIARIES OF A PRIVATE HEALTH PLAN IN BRAZIL
	Reis Neto JP, Stefani S
	CAPESESP/CAPESAUDE, Rio de Janeiro, RJ, Brazil